

ID V61168 standard; cDNA; 234 BP.

```
AC V61168:
DT 06-JAN-1999 (first entry)
DE cDNA sequence of prostate tumour clone P20.
KW Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN WO9837093-A2.
PD 27-AUG-1998.
PE 25-FEB-1998; US-020956.
PR 09-FEB-1998; US-020956.
PR 25-FEB-1997; US-806099.
PR 01-AUG-1997; US-904804.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J.
DR WPI: 98-609886/51.
PT Polypeptides comprising immunogenic portions of prostate proteins -
PS used in a vaccine for the treatment of prostate cancer
PS Claim 3; Page 53-54; 130pp; English.
CC The present sequence is a new DNA which encodes an immunogenic portion
CC of a prostate tumour protein. The encoded immunogen, or the DNA itself,
CC can be used as a vaccine for the treatment of prostate cancer. The DNA
CC was identified by analysis of a subtracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
CC tissue cDNA library.
SQ Sequence 234 BP; 43 A; 68 C; 68 G; 55 T;

Query Match 100.0%; Score 234; DB 1; Length 234;
Best Local Similarity 100.0%; Pred. No. 2.4e-61;
Matches 234; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 acaacagacccttgctcgtctaacgacctatgctcatcaagtgtgacgaatccgtgtcg 60
DB 1 ACAACAGACCCCTTGCTCGCTTAAGACCTCATCTCATCAAGTTGGAGATCCGTGTCCG 60
QY 61 agctgcacacatccggagacatcagcattgcttcgagtgccctaccgagggaactctt 120
DB 61 AGCTGCACACCATCCGGACATCAGCATTCCTTCGCAAGTCCCTACCGGGGAACTCTT 120
QY 121 gccctgttcctgctgggggtgctgtctggcgaaagcgagaaatgcttaccggtgagtg 180
DB 121 GCCTGCTTCTGCTGGGTGCTGTGCTGCGAAGCGCAATGCTTACCGCTGCACTGCG 180
QY 181 tgaacgtgtcgggtgtgtctgtgagagagcttcgagtaagctctatgacccgctgt 234
DB 181 TGAAGTGTGCGGTGTGTCTGTGAGAGAGTCTGCAGTAAGCTTATGACCGCTGT 234

RESULT 3
AC V58644 standard; cDNA; 1248 BP.
DE 08-DEC-1998 (first entry)
KW Prostate tumour specific gene clone DEL.
KW Prostate tumour specific gene; human; prostate cancer; detection;
OS Homo sapiens.
FH Key Location/Qualifiers
FT CDS 217..696
FT /tag= a
PN WO9837418-A2.
PD 27-AUG-1998.
PE 25-FEB-1998; US-03690.
PR 09-FEB-1998; US-904809.
PR 25-FEB-1997; US-806596.
PR 01-AUG-1997; US-904809.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J.
DR WPI: 98-480805/41.
DR P-PSDB: W69387.
PT Novel human prostate specific tumour protein and fragments - useful
PT for detecting and treating prostate cancers
PS Claim 1; Page 112; 141pp; English.
CC This sequence represents a human prostate tumour specific gene, and can
```

```
CC be used in the method of the invention. The method is for detecting
CC prostate cancer comprising contacting a biological sample with an agent
CC able to bind an immunogenic portion of a prostate protein (such as
CC encoded by this sequence). An antibody which binds to an immunogenic
CC portion of the prostate protein, and the method can be used to detect,
CC monitor progression of, or treat prostate cancers. The antibody may
CC also be conjugated to a therapeutic agent for use in therapy of prostate
CC cancers.
SQ Sequence 1248 BP; 288 A; 424 C; 303 G; 228 T;

Query Match 100.0%; Score 234; DB 1; Length 1248;
Best Local Similarity 100.0%; Pred. No. 3.8e-61;
Matches 234; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 acaacagacccttgctcgtctaacgacctatgctcatcaagtgtgacgaatccgtgtcg 60
DB 254 ACAACAGACCCCTTGCTCGCTTAAGACCTCATCTCATCAAGTTGGAGATCCGTGTCCG 313
QY 61 agctgcacacatccggagacatcagcattgcttcgagtgccctaccgagggaactctt 120
DB 61 AGCTGCACACCATCCGGACATCAGCATTCCTTCGCAAGTCCCTACCGGGGAACTCTT 373
QY 121 gccctgttcctgctgggggtgctgtctggcgaaagcgagaaatgcttaccggtgagtg 180
DB 374 GCCTGCTTCTGCTGGGTGCTGTGCTGCGAAGCGCAATGCTTACCGCTGCACTGCG 433
QY 181 tgaacgtgtcgggtgtgtctgtgagagagcttcgagtaagctctatgacccgctgt 234
DB 434 TGAAGTGTGCGGTGTGTCTGTGAGAGAGTCTGCAGTAAGCTTATGACCGCTGT 487

RESULT 4
ID V61249 standard; cDNA; 1248 BP.
AC V61249;
DE 06-JAN-1999 (first entry)
DE cDNA sequence of prostate tumour clone P703 splice variant DEL.
KW Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN WO9837093-A2.
PD 27-AUG-1998.
PE 25-FEB-1998; US-03492.
PR 09-FEB-1998; US-020956.
PR 25-FEB-1997; US-806099.
PR 01-AUG-1997; US-904804.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J.
DR WPI: 98-609886/51.
DR P-PSDB: W71871.
PT Polypeptides comprising immunogenic portions of prostate proteins -
PT used in a vaccine for the treatment of prostate cancer
PS Claim 3; Page 104; 130pp; English.
CC The present sequence is a new DNA which encodes an immunogenic portion
CC of a prostate tumour protein. The encoded immunogen, or the DNA itself,
CC can be used as a vaccine for the treatment of prostate cancer. The DNA
CC was identified by analysis of a subtracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
CC tissue cDNA library.
SQ Sequence 1248 BP; 288 A; 424 C; 303 G; 228 T;

Query Match 100.0%; Score 234; DB 1; Length 1248;
Best Local Similarity 100.0%; Pred. No. 3.8e-61;
Matches 234; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 acaacagacccttgctcgtctaacgacctatgctcatcaagtgtgacgaatccgtgtcg 60
DB 254 ACAACAGACCCCTTGCTCGCTTAAGACCTCATCTCATCAAGTTGGAGATCCGTGTCCG 313
QY 61 agctgcacacatccggagacatcagcattgcttcgagtgccctaccgagggaactctt 120
DB 61 AGCTGCACACCATCCGGACATCAGCATTCCTTCGCAAGTCCCTACCGGGGAACTCTT 373
QY 121 gccctgttcctgctgggggtgctgtctggcgaaagcgagaaatgcttaccggtgagtg 180
DB 374 GCCTGCTTCTGCTGGGTGCTGTGCTGCGAAGCGCAATGCTTACCGCTGCACTGCG 433
QY 181 tgaacgtgtcgggtgtgtctgtgagagagcttcgagtaagctctatgacccgctgt 234
DB 434 TGAAGTGTGCGGTGTGTCTGTGAGAGAGTCTGCAGTAAGCTTATGACCGCTGT 487
```

Query Match	100.0%	Score 234:	DB 1:	Length 1386:
Best Local Similarity	100.0%	Pred. No. 3.9e-61:		
Matches 234:	Conservative 0:	Mismatches 0:	Indels 0:	Gaps 0:
Db	1	acaacagaccccttgcctgctacagacccatgctcatcaagttgacagatccgctgctcg	60	
Db	234	ACAACAGACCCTTGTCTGCTACGACCCATCAGATTGCTTCGACGTGCCCTACCGGGGAACTCTT	293	
Db	61	agtcgaacccatccgcggagcatcagcatgtcttgagtgccctacgcggggaactctt	120	
Db	294	ACTCTGACACCAATCCGGACATCAGATTGCTTCGACGTGCCCTACCGGGGAACTCTT	353	
Db	121	gcctgtttcttgctgagtgctgctgacgacagagaggaatgctctacggtgcgaatgctg	180	
Db	354	GCCTGTTCTTCTGCTGAGGCTCTGCTGCGCAAGCGCAGATGCCCTACCGGTCTGCACTGCG	413	
Db	181	tgaacgtctcggtgtgtgtctgaggaaggtctgcagtaagctctatgacccgctgt	234	
Db	434	TGAACGTCTCGGTGTGTCTGAGGAGGTCTGCAAGTAAAGCTTATGACCCGCTGT	487	

RESULT	6	
ID	V58647	standard; cDNA; 1167 BP.
AC	V58647:	
DT	08-DEC-1998	(first entry)
DE	Prostate tumour specific gene clone DE13.	
KW	Prostate tumour specific gene; human; prostate cancer; detection;	
OS	therapy; ss.	
OS	Homo sapiens.	
FH	Key	Location/Qualifiers
FT	CDS	28..645
FT	/*tag= a	
PN	W09837418-A2.	
PD	27-AUG-1998.	
PF	25-FEB-1998:	U03690.
PR	09-FEB-1998:	US-904809.
PR	25-FEB-1997:	US-806596.
PR	01-AUG-1997:	US-904809.
PA	(CORI-) CORIXA CORP.	
PI	Dillon DC, Xu J;	
DR	WPI: 98-440805/41.	
DR	P-PSDB: W69388.	
PT	Novel human prostate specific tumour protein and fragments - useful	
PT	for detecting and treating prostate cancers	
PT	Claim 1; Page 115; 141pp: English.	
CC	This sequence represents a human prostate tumour specific gene, and can	
CC	be used in the method of the invention. The method is for detecting	
CC	prostate cancer comprises contacting a biological sample with an agent	
CC	able to bind an immunogenic portion of a prostate protein (such as	
CC	encoded by this sequence). An antibody which binds to an immunogenic	
CC	portion of the prostate protein, and the method can be used to detect,	
CC	monitor progression of, or treat prostate cancers. The antibody may	
CC	also be conjugated to a therapeutic agent for use in therapy of prostate	
CC	cancers.	
CC	Sequence 1167 BP; 242 A; 400 C; 287 G; 222 T;	
Query Match	97.8%; Score 228.8; DB 1; Length 1167;	
Best Local Similarity	98.3%; Pred. No. 1.3e-59;	
Matches 230; Conservative	0; Mismatches 4; Indels 0; Gaps 0;	
0Y	1 aaaaagacccttgctgctcaacgacctatgctcatcaagtgtgacgaatccgtgtcgcg 60	
Db	203 ACAACAGACTCTTGTCTCGCTACGACCTCATCTCATCAAGTGGACGAATCCGTGTCG 262	
0Y	61 agcttgaaccacccgcggagcatcaagcatgtgttcgcagtcgcccaccgcggggaactctt 120	
Db	263 AACTGACACCACTCCGGAGCATCAGACATTCATTCGTTCGCAATGCCCTACCCGGGAACCTT 322	
0Y	121 gctcgtttcttgagctgagggtctgctgtgcgaacgagagaatgctaccgctgtcagtcg 180	
Db	323 GCCTGCTMTCTGGCTGGGGGTCTGCTGCGGAACGCGCAAGTGCCTACCGTGCACCTGCG 382	
0Y	181 tgaagttcgtgtgtgtctcagagagagcttcgacgtaaactctatgacccgctgtc 234	
Db	383 TGAACGTGCTGGTGTGTCTGTGAGGANGTCTGCAGTAACTCATGACCCGCGTGT 436	
RESULT	7	
ID	V61252	
AC	V61252 standard; cDNA; 1167 BP.	
DT	06-JAN-1999	(first entry)
DE	cDNA sequence of prostate tumour clone P703 splice variant DE13.	
KW	Prostate; cancer; tumour; vaccine; immunogen; clone; ss.	
OS	Homo sapiens.	
PN	W09837093-A2.	
PD	27-AUG-1998.	
PF	25-FEB-1998:	U03492.

Query Match 66.2%; Score 155; DB 1; Length 402;
Best Local Similarity 100.0%; Pred. No. 1.2e-37;
Matches 155; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 acacagacccttgctgcgtacagaccatcatgctcatcaagttgagcaatcgtgtccg 60
DB 242 ACAACAGACCCCTTGCTGCTACAGACCTCATGCTCATCAAGTTGAGCAATCCGTGTCG 301
QY 61 agctgcaccatccgagacatcagcatctgtctgcagtgccctaccgcggggaactctt 120
DB 302 AGCTGACACCATCCGAGCATGCAATGCTTCGACATGCCCTACCGCGGGGAACCTCTT 361
QY 121 gctcgttctgctggtggtctgtctgcggaacggc 155
DB 362 GCCCTGTTCTGCTGGGGGCTGCTGGGAGACGCG 396

BLT 10

V58645
ID V58645 standard; cDNA; 1265 BP.
AC V58645;
DT 08-DEC-1998 (first entry)
DE Prostate tumour specific gene clone DE2.
KW Prostate tumour specific gene; human; prostate cancer; detection;
KM therapy; ss.
OS Homo sapiens.
PN WO9837418-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; US-904809.
PR 09-FEB-1998; US-904809.
PR 25-FEB-1997; US-806596.
PR 01-AUG-1997; US-904809.
PA (COR-) CORIXA CORP.
PI Dillion DC, Xu J;
DR WPI: 98-480805/41.
PT Novel human prostate specific tumour protein and fragments - useful
PS for detecting and treating prostate cancers
PS Claim 1: Page 113-114; 141pp; English.
CC This sequence represents a human prostate tumour specific gene, and can
CC be used in the method of the invention. The method is for detecting
CC prostate cancer comprises contacting a biological sample with an agent
CC able to bind an immunogenic portion of a prostate protein (such as
CC encoded by this sequence). An antibody which binds to an immunogenic
CC portion of the prostate protein, and the method can be used to detect,
CC monitor progression of, or treat prostate cancers. The antibody may
CC also be conjugated to a therapeutic agent for use in therapy of prostate
CC cancers.
SQ Sequence 1265 BP; 256 A; 432 C; 321 G; 245 T;

Query Match 65.8%; Score 154; DB 1; Length 1265;
Best Local Similarity 100.0%; Pred. No. 3.1e-37;
Matches 154; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 acacagacccttgctgcgtacagaccatcatgctcatcaagttgagcaatcgtgtccg 60
DB 215 ACAACAGACCCCTTGCTGCTACAGACCTCATGCTCATCAAGTTGAGCAATCCGTGTCG 274
QY 61 agctgcaccatccgagacatcagcatctgtctgcagtgccctaccgcggggaactctt 120
DB 275 AGCTGACACCATCCGAGCATGCAATGCTTCGACATGCCCTACCGCGGGGAACCTCTT 334
QY 121 gctcgttctgctggtggtctgtctgcggaacgg 154
DB 335 GCCCTGTTCTGCTGGGGGCTGCTGGGAGACGCG 368

RESULT 11
V61250
ID V61250 standard; cDNA; 1265 BP.
AC V61250;

DT 06-JAN-1999 (first entry)
DE cDNA sequence of prostate tumour clone P703 splice variant DE2.
KW Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN WO9837093-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; US-90492.
PR 09-FEB-1998; US-020956.
PR 25-FEB-1997; US-806099.
PR 01-AUG-1997; US-904804.
PA (COR-) CORIXA CORP.
PI Dillion DC, Xu J;
DR WPI: 98-609886/51.

PT Polypeptides comprising immunogenic portions of prostate proteins -
PT used in a vaccine for the treatment of prostate cancer
PS Claim 3: Page 105-106; 130pp; English.
CC The present sequence is a new DNA which encodes an immunogenic portion
CC of a prostate tumour protein. The encoded immunogen, or the DNA itself,
CC can be used as a vaccine for the treatment of prostate cancer. The DNA
CC was identified by analysis of a subtracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
CC tissue cDNA library.
SQ Sequence 1265 BP; 256 A; 432 C; 321 G; 245 T;

Query Match 65.8%; Score 154; DB 1; Length 1265;
Best Local Similarity 100.0%; Pred. No. 3.1e-37;
Matches 154; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 acacagacccttgctgcgtacagaccatcatgctcatcaagttgagcaatcgtgtccg 60
DB 215 ACAACAGACCCCTTGCTGCTACAGACCTCATGCTCATCAAGTTGAGCAATCCGTGTCG 274
QY 61 agctgcaccatccgagacatcagcatctgtctgcagtgccctaccgcggggaactctt 120
DB 275 AGCTGACACCATCCGAGCATGCAATGCTTCGACATGCCCTACCGCGGGGAACCTCTT 334
QY 121 gctcgttctgctggtggtctgtctgcggaacgg 154
DB 335 GCCCTGTTCTGCTGGGGGCTGCTGGGAGACGCG 368

RESULT 12

V58646
ID V58646 standard; cDNA; 1459 BP.

DT 08-DEC-1998 (first entry)
DE Prostate tumour specific gene clone DE6.
KW Prostate tumour specific gene; human; prostate cancer; detection;
KM therapy; ss.

OS Homo sapiens.
PN WO9837418-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; US-904809.
PR 09-FEB-1998; US-904809.
PR 25-FEB-1997; US-806596.
PR 01-AUG-1997; US-904809.
PA (COR-) CORIXA CORP.
PI Dillion DC, Xu J;
DR WPI: 98-480805/41.
PT Novel human prostate specific tumour protein and fragments - useful
PT for detecting and treating prostate cancers
PS Claim 1: Page 114; 141pp; English.
CC This sequence represents a human prostate tumour specific gene, and can
CC be used in the method of the invention. The method is for detecting
CC prostate cancer comprises contacting a biological sample with an agent
CC able to bind an immunogenic portion of a prostate protein (such as
CC encoded by this sequence). An antibody which binds to an immunogenic
CC portion of the prostate protein, and the method can be used to detect,
CC monitor progression of, or treat prostate cancers. The antibody may
CC also be conjugated to a therapeutic agent for use in therapy of prostate
CC cancers.
SQ Sequence 1459 BP; 427 A; 328 C; 406 G; 295 T;

Query Match 65.8%; Score 154; DB 1; Length 1459;
Best Local Similarity 100.0%; Pred. No. 3.2e-37;
Matches 154; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 acacagacccctgtctgctacagacccatcctcatcacaagtgtggaacatccgtgtccg 60
DB 136 ACAACAGACCCCTGTGCTGCTAAGACGACCTCATCCTCATCAAGTTGACGACATCCGTGTCG 195
QY 61 agcttgacacacatccggagacatcagcatgtctgcagttgccctacgcgcggggaactctt 120
DB 196 AGCTGACACCATCCGGAGACATCAGCATTTGCTTCCAGATGCCCTACCGCGGGAACCTCTT 255
QY 121 gccctgttctggctgggtgtctgtcgtggcgaacgg 154
DB 256 GCCTCGTTTCTGCTGGGTGCTGCTGCGGACGG 289

RESULT 13
V61251 standard; cDNA; 1459 BP.
AC V61251;
DT 06-JAN-1999 (first entry)
DE cDNA sequence of prostate tumour clone P703 splice variant DE6.
KW Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN M09837093-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; U03492.
PR 09-FEB-1998; US-020956.
PR 25-FEB-1997; US-806099.
PR 01-AUG-1997; US-904804.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI: 98-609886/51.
PT Polypeptides comprising immunogenic portions of prostate proteins -
used in a vaccine for the treatment of prostate cancer
PS Claim 1; Page 106; 130pp; English.
CC The present sequence is a new DNA which encodes an immunogenic portion
of a prostate tumour protein. The encoded immunogen, or the DNA itself,
can be used as a vaccine for the treatment of prostate cancer. The DNA
was identified by analysis of a subtracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
tissue cDNA library.
Sequence 1459 BP; 427 A; 328 C; 406 G; 295 T;

Query Match 65.8%; Score 154; DB 1; Length 1459;
Best Local Similarity 100.0%; Pred. No. 3.2e-37;
Matches 154; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 acacagacccctgtctgctacagacccatcctcatcacaagtgtggaacatccgtgtccg 60
DB 136 ACAACAGACCCCTGTGCTGCTAAGACGACCTCATCCTCATCAAGTTGACGACATCCGTGTCG 195
QY 61 agcttgacacacatccggagacatcagcatgtctgcagttgccctacgcgcggggaactctt 120
DB 196 AGCTGACACCATCCGGAGACATCAGCATTTGCTTCCAGATGCCCTACCGCGGGAACCTCTT 255
QY 121 gccctgttctggctgggtgtctgtcgtggcgaacgg 154
DB 256 GCCTCGTTTCTGCTGGGTGCTGCTGCGGACGG 289

RESULT 14
V58648 standard; cDNA; 1119 BP.
ID V58648;
AC V58648;
DT 08-DEC-1998 (first entry)
DE Prostate tumour specific gene clone DE14.
KW Prostate tumour specific gene; human; prostate cancer; detection;
therapy; ss.

OS Homo sapiens.
FH Key Location/Qualifiers
FT CDS 34..528
FT CDS /*tag= a
FN M09837418-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; U03690.
PR 09-FEB-1998; US-904809.
PR 25-FEB-1997; US-806596.
PR 01-AUG-1997; US-904809.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI: 98-480805/41.
DR P-PSDB: W69389.
PT Novel human prostate specific tumour protein and fragments - useful
for detecting and treating prostate cancers
PS Claim 1; Page 116-117; 141pp; English.
CC This sequence represents a human prostate tumour specific gene, and can
be used in the method of the invention. The method is for detecting
CC prostate cancer comprises contacting a biological sample with an agent
able to bind an immunogenic portion of a prostate protein (such as
CC encoded by this sequence). An antibody which binds to an immunogenic
CC portion of the prostate protein, and the method can be used to detect,
CC monitor progression of, or treat prostate cancers. The antibody may
CC also be conjugated to a therapeutic agent for use in therapy of prostate
cancers.
Sequence 1119 BP; 248 A; 305 C; 282 G; 284 T;

Query Match 65.7%; Score 153.8; DB 1; Length 1119;
Best Local Similarity 93.1%; Pred. No. 3.4e-37;
Matches 161; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 1 acacagacccctgtctgctacagacccatcctcatcacaagtgtggaacatccgtgtccg 60
DB 209 ACAACAGACCCCTGTGCTGCTAAGACGACCTCATCCTCATCAAGTTGACGAAATCCGTGTCG 268
QY 61 agcttgacacacatccggagacatcagcatgtctgcagttgccctacgcgcggggaactctt 120
DB 269 AGCTGACACCATCCGGAGACATCAGCATTTGCTTCCAGATGCCCTACCGCGGGAACCTCTT 328
QY 121 gccctgttctggctgggtgtctgtcgtggcgaacgg 173
DB 329 GCCTCGTTTCTGCTGGGTGCTGCTGCGGACGATGCTGATTCGATCCATCCAG 381

RESULT 15
V61253 standard; cDNA; 1119 BP.
ID V61253;
AC V61253;
DT 06-JAN-1999 (first entry)
DE cDNA sequence of prostate tumour clone P703 splice variant DE14.
KW Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN M09837093-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; U03492.
PR 09-FEB-1998; US-020956.
PR 25-FEB-1997; US-806099.
PR 01-AUG-1997; US-904804.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI: 98-609886/51.
DR P-PSDB: W71873.
PT Polypeptides comprising immunogenic portions of prostate proteins -
used in a vaccine for the treatment of prostate cancer
PS Claim 3; Page 108-109; 130pp; English.
CC The present sequence is a new DNA which encodes an immunogenic portion
of a prostate tumour protein. The encoded immunogen, or the DNA itself,
can be used as a vaccine for the treatment of prostate cancer. The DNA
was identified by analysis of a subtracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
tissue cDNA library.

Sequence 1119 BP; 248 A; 305 C; 282 G; 284 T;

Query Match 65.7%; Score 153.8; DB 1; Length 1119;
 Best Local Similarity 93.1%; Pred. No. 3.4e-37;
 Matches 161; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 1 acacagaccccttgcctgaacgacccctcaatgctcaatgaagttgagcgaatccgtgtccg 60
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 209 ACAACAGACCCCTTGCTGCTAACGACCTCATGCTCATCAAGTTGAGCATCCGTGTCCG 268
 QY 61 agctcgaacaccatccggaagcatcagcatgtcttcgcaagtgcctaccgcyggaactctt 120
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 269 AGTCTGACACCATCCGAGCATCAGCATGTCTTCGACAGTGCCTACCCGCGGGAACCTT 328
 QY 121 gctcgtttctggtggt 173
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 329 GCCTCGTTCTGGGTGGGT 381

Search completed: June 19, 2000, 18:55:38
 Job time: 4033 Sec

This Page Blank (uspto)

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 19, 2000, 18:55:47 ; Search time 94.16 seconds
(without alignments)
4307.151 Million cell updates/sec

Title: US-09-232-880-107
Perfect score: 1621
Sequence: 1 cgcctatgacactgcagggca.....aaaaaaaaaaaaaaaa 1621

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Number of hits satisfying chosen parameters: 623170

Minimum DB seq length: 0
Maximum DB seq length: 1000000

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database : N_Geneseq_36.*
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	ID	Description
1	1621	100.0	1621	Prostate tumour sp
2	1621	100.0	1621	Full length CDNA s
3	515	31.8	537	Prostate tumour sp
4	515	31.8	537	CDNA sequence of p
5	406.6	25.1	773	5' fragment of pro
6	406.6	25.1	773	3' fragment of pro
7	403.2	24.9	793	3' fragment of pro
8	403.2	24.9	793	3' CDNA sequence o
9	400.2	24.7	816	3' fragment of pro
10	400.2	24.7	816	3' CDNA sequence o
11	248.2	15.3	1462	Cephalosporin C CD
12	234.8	14.5	5537	Cephalosporin C ge
13	67.8	4.2	2123	PTH-like peptide D
14	66.6	4.1	208	3' nucleotide sequ
15	65.2	4.0	4237	Human secreted pro
16	63.4	3.9	1172	Protein allergen o
17	62.8	3.9	1534	Human interleukin-
18	62.2	3.8	2094	Human secreted pro
19	62.2	3.8	2447	Human secretory pr
20	62	3.8	1474	Oil seed rape cyst
21	62	3.8	1474	Clone CT797_3 codi
22	61.2	3.8	2594	Melon aconitase cd
23	60.8	3.8	270	Hepatitis C virus
24	60.8	3.8	1733	Human tumour anti
25	60	3.7	1220	Human secreted pro
26	59.8	3.7	2339	Tomato acid invert
27	59.8	3.7	2339	Tomato acid invert
28	59.8	3.7	2634	S. tuberosum isoam
29	59.6	3.7	1261	Human secreted pro
30	59.6	3.7	1641	Human interleukin-
31	59.4	3.7	7753	Normal virus stia
32	59.2	3.7	1558	Survival motor neu
33	59.2	3.7	1560	Human survival mot
34	59.2	3.7	1582	Human survival mot

35	59.2	3.7	1582	1	T28259	Survival motor neu
36	59.2	3.7	2001	1	T59700	PTH-like peptide D
37	59.2	3.7	2427	1	004107	Human pro-urokinas
38	58.6	3.6	2233	1	V10120	Human retinoid rec
39	58.6	3.6	2277	1	Q20360	Human pro-urokinas
40	58.6	3.6	6644	1	X33181	Base sequence of t
41	58.6	3.6	7372	1	X33182	Base sequence of t
42	58.6	3.6	7797	1	X33180	Cowpox virus bsr f
43	58.6	3.6	7996	1	X33184	Base sequence of t
44	58	3.6	1536	1	094111	mml genomic DNA. T
45	58	3.6	2271	1	V84632	Human secreted pro

ALIGNMENTS

RESULT	ID	Score	Query Match Length	ID	Description
1	V58584	100.0%	1621	1621	Prostate tumour specific gene clone Fl-12.
2	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
3	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
4	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
5	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
6	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
7	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
8	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
9	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
10	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
11	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
12	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
13	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
14	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
15	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
16	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
17	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
18	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
19	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
20	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
21	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
22	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
23	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
24	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
25	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
26	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
27	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
28	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
29	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
30	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
31	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
32	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
33	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
34	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
35	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
36	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
37	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
38	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
39	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
40	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
41	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
42	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
43	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
44	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.
45	V58584	100.0%	1621	1621	Prostate tumour specific gene; human; prostate cancer; detection.

```

OY 241 ctccgcgcggtgtcaltgsgaagctccagctgggcccagagatctgcagcgggaaaa 300
    |||
Db 241 CTTCCGCCGCGGTGTCAATGAGAACTCCAGCTGGGCCAGAGATTTCAGACGGGAAAA 300
OY 301 tccaaggttattatgccaagctgagtgatgttggccaagtcagaagactctgcggtt 360
    |||
Db 301 TCANAAGCTTATTATGCGAGGCTGAGTGGATTGGCCAGTCAGGAACCTTCTGCCGTT 360
OY 361 agctggccagatatacaactattgctcttcaagtgctctctcaaaaattgscagaag 420
    |||
Db 361 AGCTGGCCAGATATCACTATTGGCTTTGTCAGAGTCTTCTCAAAAATTGGCAGAG 420
OY 421 tgtgtgaagatccgtatgccccgcgtgaatccctcgtgtaacttgcgtgtgtgacctat 480
    |||
Db 421 TGGTGAATCCGATGCCCCCGCTGAATCTCTGCTACTTCTGCTGGTGGGCTTAT 480
OY 481 gttgtgcaatggcattataatgctcttttgaacgcagacagcatgtgcaaggtcaggt 540
    |||
Db 481 GTGTGCACTGGGCAATTATATAGGCTCTTTTGACCGCACGCACTGACAGAGGTCAGGT 540
OY 541 catgatgcaaatatgtgtgaagagacagcaattataagctctcttctgtggaaccca 600
    |||
Db 541 CATGATGCAAAATATGCTGGAGAGACAGCATATTAGTTCTTTCTGTGGAACCTCA 600
OY 601 gaaatcgagctctgtggaagacacctcgagagacagaacatgttgaatgtgagcacctt 660
    |||
Db 601 GAAATCGAGCTGTGGAGACACCTCGAGACAGAACATGTTGATGGTGAAGCACCTT 660
OY 661 ctatacgacttaacagagagacagatggggaattctatgctgttggagaatagaaaccca 720
    |||
Db 661 CTATACGACTTACAGAGACAGATGGGGAAATTCATGGCTGTGGAGAAATGAAGCCCA 720
OY 721 gttctacagctgtcgtatcaaaagaccttgaactaagctctatgtaacttcccaatcagat 780
    |||
Db 721 GTTCTACAGCTGTGATGATCAAGGACTTGACATAAGCTGATGACTTCCCAATCAAT 780
OY 781 gagcatggaatgtgtgccaagaatagaagaagatgtgcagatgtatattgcaaaagaac 840
    |||
Db 781 GAGCATGATGATTTGGCCAGAAATGAAGAAATTTGCAATGATTTGCAAAAGAAC 840
OY 841 gaaagcagagtggtgtcaaatctttagagcagacatgtcctgtgtaactccggtcttac 900
    |||
Db 841 GAAAGCAGAGTGTGTCAAACTTTGAGGCAACATCCCTGTGTGACTCCGGTCTTAC 900
OY 901 ttctgagaggtgtgtcatcatcatcatcaacaagaagcggtcgtttatcaccagtg 960
    |||
Db 901 TTTTGAGAGAGTGTGTCTCATGATCACAACAGAGAGGGGCTGTTATCACCAGTGA 960
OY 961 ggaagcagagtgagccccgcgacctgcaactcgtgtttaaaccaccagcaccatccctt 1020
    |||
Db 961 GGAGCAGAGACTGAGCCCCCGCCCTGCACCTCTGCTTTAAACACCCAGCAGCATCCCTTC 1020
OY 1021 tttaaaaggatctcttcatagagagacacatgagagatcttgaagaatttgatc 1080
    |||
Db 1021 TTTCAAAAGGATCTTTCATATGAGAACACACTGAGAGATCTTGAAGATTGGATT 1080
OY 1081 cagcgcgaagaagattatcagcttaactcagataaatacttgaagtaataaggttaa 1140
    |||
Db 1081 CAGCGCGAAGATTTATATGCTTAAGCTTAAGTAAATCTTTGAAGTAAAGTAA 1140
OY 1141 agctagctcctaacttccagggcccaaggtcaagtgaaattgaaatactgtcaatg 1200
    |||
Db 1141 AGCTAGTCTTAACCTTCAGGCCCCAGGCTCAAGTGAATTGGAATATGCAATTAACA 1200
OY 1201 taaggtatacaataacttgaatgtatgtgaagaatgtgaggaacagatatacaagtccta 1260
    |||
Db 1201 TAGAGTAAACATATCATTTATGATGAGAAACATGAGGAACAGTATTTAGAGTCTCTA 1260
OY 1261 ccaactcaatcaagaagaagaattacagacactgtattctacagtgatgttgaattcraa 1320
    |||
Db 1261 CCACTCTAATCAAAAAAGATTACAGACTGTGATTTCTACAGTGTGATTTAAATTTCTAA 1320
OY 1321 aatgttatcatagggctttagattataaaacttgggtactataactaaatattgt 1380

```

```

Db 1321 AATGTTATCATATAGGCTTTGATTATAAACTTTGGTACTTATACATAATTATGT 1380
OY 1381 agttatctgcctccagttgtgtgatataattgtgtatataagattcttgactata 1440
    |||
Db 1381 AGTTATCTGCTTCCAGTTGCTTGAATATTTGTTGATATTAAGATTCTTGACTTATA 1440
OY 1441 ttctgaatgggtctcagtgaaagaatgatatattcttgaagacatcgaatacatt 1500
    |||
Db 1441 TTTGAATGGGTTCTAGGAAAAAGATGATATATTCTTAACACATCATATACATT 1500
OY 1501 attacactcttgattctacaaatgtagaaatgsgaagaatgccaaattgtatgtat 1560
    |||
Db 1501 ATTACACTCTTGTATTCTACATGTAGAAATGAGAAATGCCCAAAATTGATGTAT 1560
OY 1561 aaaaagtcagtgaaacaaaaaataaaaaaataaaaaaataaaaaaataaaaaa 1620
    |||
Db 1561 AAAAGTCAGTGAACAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 1620
OY 1621 a 1621
    |||
Db 1621 A 1621

RESULT 2
V61199
ID V61199 standard; cDNA: 1621 BP.
AC V61199:
DT 06-JAN-1999 (first entry)
DE Full length cDNA sequence of prostate tumour clone F1-12.
KW Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN M09837093-A2.
PD 27-AUG-1998
PE 25-FEB-1998; U03492.
PR 09-FEB-1998; US-020956.
PR 25-FEB-1997; US-806099.
PR 01-AUG-1997; US-904804.
PA (CORI-) CORIAX CORP.
PI Dillon DC, Xu J.
DR WPI: 98-609886/51.
DR P-PSDB: W71867.
PT Polypeptides comprising immunogenic portions of prostate proteins -
PT used in a vaccine for the treatment of prostate cancer
PS Claim 3: Page 76-77; 130pp; English.
CC The present sequence is a new DNA which encodes an immunogenic portion
CC of a prostate tumour protein. The encoded immunogen, or the DNA itself,
CC can be used as a vaccine for the treatment of prostate cancer. The DNA
CC was identified by analysis of a subtracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
CC tissue cDNA library.
SO Sequence 1621 BP; 461 A; 330 C; 412 G; 418 T;

Query Match 100.0%; Score 1621; DB 1; Length 1621;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1621; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 cgccatggcactgcaaggcatctgctatgagctgtccggcctggccccgggcccgt 60
    |||
Db 1 CGCCATGGCACTGCAGGGCATCTCGTCATGAGACTGTCCGGCTGGCCCCGGCGCTT 60
OY 61 ctgtgcatgttctgtgctgacttcggggcggtgtgtatcggtgtgacggccggctc 120
    |||
Db 61 CTGTGCTATGCTCTGTGCTGCTGACTTGGGGCGCGGTGTGTAGCGCTGAGCCGGCCGCTC 120
OY 121 ccgctacagacgtgagccgctgtgagccgggcaagcgctcgtatgtgtgacctgaagca 180
    |||
Db 121 CCGCTACAGACGTGAGCCGCTTGGGCCGGGGCAACGCTCGCTAGCTGTGAACTGAAGCA 180
OY 181 gcgcggggagccgcgtgtcgtcggtctctgtgcaagcgggtcggatgtgtcgtcgagcc 240
    |||
Db 181 GCCCGGGGAGCCCGCGTGTGCGGCTGTGTGCAACGCGGAGTGTGCTGTGAGGCC 240

```

```

QY 241 ctcgcgcgcgtgtcaltgagaaacccagctggtgcccagagattctgcacgcygaa 300
D 241 ctcgcgcgcgcgtgtcaltgagaaacccagctggtgcccagagattctgcacgcygaa 300
QY 301 tccaagagcttattatgcagagctgagtgatgttgccagtcaggaagctctgcaggt 360
D 301 tccaagagcttattatgcagagctgagtgatgttgccagtcaggaagctctgcaggt 360
QY 361 agctggccacatatacaactatttgcttgcttgcttgcttgcttgcttgcttgcttg 420
D 361 agctggccacatatacaactatttgcttgcttgcttgcttgcttgcttgcttgcttg 420
QY 421 tggtagaagctcgtatgcagcgcgtgacccctgctgctgctgctgctgctgctgct 480
D 421 tggtagaagctcgtatgcagcgcgtgacccctgctgctgctgctgctgctgctgct 480
QY 481 gctgacactggtcattatattgctcttcttgacccgcacagcagctgacaggtcaggt 540
D 481 gctgacactggtcattatattgctcttcttgacccgcacagcagctgacaggtcaggt 540
QY 541 catgattgcaaatatggtgagaaagcagcagcagcagcagcagcagcagcagcagc 600
D 541 catgattgcaaatatggtgagaaagcagcagcagcagcagcagcagcagcagcagc 600
QY 601 gaaatcgagctctgaggaagcagcagcagcagcagcagcagcagcagcagcagcagc 660
D 601 gaaatcgagctctgaggaagcagcagcagcagcagcagcagcagcagcagcagcagc 660
QY 661 ctatacagctcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 720
D 661 ctatacagctcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 720
QY 721 gttctacagctctgctatcaagaagctgagcagcagcagcagcagcagcagcagcag 780
D 721 gttctacagctctgctatcaagaagctgagcagcagcagcagcagcagcagcagcag 780
QY 781 gagcagctgagctgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 840
D 781 gagcagctgagctgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 840
QY 841 gaaagcagcagctgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 900
D 841 gaaagcagcagctgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 900
QY 901 tttgagagagctgttctatcatatcatatcatatcatatcatatcatatcatatcatat 960
D 901 tttgagagagctgttctatcatatcatatcatatcatatcatatcatatcatatcatat 960
QY 961 ggaagcagcagctgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 1020
D 961 ggaagcagcagctgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 1020
QY 1021 tttcaaaaagagctgttctatcatatcatatcatatcatatcatatcatatcatatcat 1080
D 1021 tttcaaaaagagctgttctatcatatcatatcatatcatatcatatcatatcatatcat 1080
QY 1081 cagccgcgagagagctgttctatcatatcatatcatatcatatcatatcatatcatatcat 1140
D 1081 cagccgcgagagagctgttctatcatatcatatcatatcatatcatatcatatcatatcat 1140
QY 1141 agctgagctcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 1200
D 1141 agctgagctcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 1200
QY 1201 tagagtaacacatacatatcatatcatatcatatcatatcatatcatatcatatcatatcat 1260
D 1201 tagagtaacacatacatatcatatcatatcatatcatatcatatcatatcatatcatatcat 1260
QY 1261 ccaactcatacaagaagaatcatagagctgattctatcagtgatgattgattctaa 1320
D 1261 ccaactcatacaagaagaatcatagagctgattctatcagtgatgattgattctaa 1320

```

```

QY 1321 aatgttcatcattagggcttcttgattataaaactttggttactatactaatatgt 1380
D 1321 aatgttcatcattagggcttcttgattataaaactttggttactatactaatatgt 1380
QY 1381 agtattctgctcctcagcttgccttgatatacttggtgatttaagattctgactata 1440
D 1381 agtattctgctcctcagcttgccttgatatacttggtgatttaagattctgactata 1440
QY 1441 tttgaatgggttctagtgaaagaatgatatattcttgaaacatcgatatatt 1500
D 1441 tttgaatgggttctagtgaaagaatgatatattcttgaaacatcgatatatt 1500
QY 1501 attacacacttctgattctacacatgtaaaatgagaaatgccaaattgattgatt 1560
D 1501 attacacacttctgattctacacatgtaaaatgagaaatgccaaattgattgatt 1560
QY 1561 aaagtcagctgaaacaaacaaacaaacaaacaaacaaacaaacaaacaaacaaacaa 1620
D 1561 aaagtcagctgaaacaaacaaacaaacaaacaaacaaacaaacaaacaaacaaacaa 1620
QY 1621 a 1621
D 1621 a 1621

RESULT 3
V58551
ID V58551 standard; cDNA; 537 BP.
AC V58551;
DT 08-DEC-1998 (first entry)
DE Prostate tumour specific gene clone R1-2330.
KW Prostate tumour specific gene; human; prostate cancer; detection;
KM therapy; ss.
OS Homo sapiens.
PN M09837418-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; U03690.
PR 09-FEB-1998; US-904809.
PR 25-FEB-1997; US-806596.
PR 01-AUG-1997; US-904809.
PA (CORI-) CORINA CORP.
PI Dillon DC, Xu J;
DR WPI: 98-480805/41.
PT Novel human prostate specific tumour protein and fragments - useful
PT for detecting and treating prostate cancers
PS Claim 1; Page 67; 141p; English.
CC This sequence represents a human prostate tumour specific gene, and can
CC be used in the method of the invention. The method is for detecting
CC prostate cancer comprises contacting a biological sample with an agent
CC able to bind an immunogenic portion of a prostate protein (such as
CC encoded by this sequence). An antibody which binds to an immunogenic
CC portion of the prostate protein, and the method can be used to detect,
CC monitor progression of, or treat prostate cancers. The antibody may
CC also be conjugated to a therapeutic agent for use in therapy of prostate
CC cancers.
SQ Sequence 537 BP; 185 A; 80 C; 98 G; 172 T;

Query Match 31.8%; Score 515; DB 1; Length 537;
Best Local Similarity 98.5%; Pred. No. 8.3e-98;
Matches 529; Conservative 0; Mismatches 7; Indels 1; Gaps 1;
QY 1036 tttcatagagaaacacactgagagagacttgaagaatttgattcagccgcgaagat 1095
D 1036 tttcatagagaaacacactgagagagacttgaagaatttgattcagccgcgaagat 1095
QY 1096 ttataagcttaacacagtaaatcatattgaaagtaagtaagtaagtaagtaagtaagtaag 1155
D 1096 ttataagcttaacacagtaaatcatattgaaagtaagtaagtaagtaagtaagtaagtaag 1155
QY 1156 tccagggccacagctcaagtgattgaattgatactcatttaagtgtaagtgtaagtaag 1215
D 1156 tccagggccacagctcaagtgattgaattgatactcatttaagtgtaagtgtaagtaag 1215
QY 1215 tccagggccacagctcaagtgattgaattgatactcatttaagtgtaagtgtaagtaag 1275
D 1215 tccagggccacagctcaagtgattgaattgatactcatttaagtgtaagtgtaagtaag 1275

```

QY 1216 catgtatgcctggaaacacatgggggaaacagatataacagtgctctccacactctcaacaga 1275
 Db 181 CATGTATGCATGGAAACAATGAGAGAAACAGATATTAAGAGTGCTCCACACTCTTAATCAAGA 240
 QY 1276 aagaattacagactcgcgattctacagtgatgatacttaacttaaaatggtatcatcattg 1335
 Db 241 AAGAATTACGAGACTCGATTCTACAGTAGATATTAAATTTAAAAAGGTAAATCATTAG 300
 QY 1336 ggcttttgattatbaaaacttgggtactatatactaaatcagtgatgtatctgccttc 1395
 Db 301 GGCTTTGATTATTAANAACCTTGGGTACTATTACTAAATTAGTAGTATTACTGCCCTTC 360
 QY 1396 cagttgctctgatataatttcttgatatacttaagaactcttgactatatttgaatgggtctc 1455
 Db 361 CAGTTGCTCTGATATATTTCTTGATATTTAAGATCTTGACTATATTTTGAATGGGTTCT 420
 QY 1456 agtgaaaaagaagatattcttttgaagaacatcgatatataacttatttaacactcttgat 1515
 Db 421 ACTGA AAAAAGAAATGATATTTCTTGAAGACATCGATATACATTTATTATACCTCTTGAT 480
 QY 1516 tctcaactctagaaaatctgagaaatgcaccaaatctgtaattggtgataaaagtcagct 1571
 Db 481 TCTCAACTCTAGAAAATGAAGAAATGCCCCCAATATCTGTGTGTGATAAAAGTCCCGT 537

RESULT 4
V61189
ID V61189 standard: cDNA: 537 BP.
AC V61189;
DT 06-JAN-1999 (first entry)
DE cDNA sequence of prostate tumour clone R1-2330.
KW Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN M09837093-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; U03492.
PR 09-FEB-1998; US-020956.
PR 25-FEB-1997; US-806039.
PR 01-AUG-1997; US-904804.
PA (CORI.) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI: 98-609886/51.
PT Polypeptides comprising immunogenic portions of prostate proteins -
PT used in a vaccine for the treatment of prostate cancer
PS Claim 3; Page 64; 130pp; English.
PP The present sequence is a new DNA which encodes an immunogenic portion
of a prostate tumour protein. The encoded immunogen, or the DNA itself
can be used as a vaccine for the treatment of prostate cancer. The DNA
was identified by analysis of a subtracted cDNA library obtained by
subtracting a prostate tumour cDNA expression library with a normal
tissue cDNA library.
SQ Sequence 537 BP; 185 A; 80 C; 98 G; 172 T;

Query Match	31.8%	Score 515;	DB 1;	Length 537;
Best Local Similarity	98.5%	Pred. No. 8.3e-98;		
Matches 529;	Conservative	0;	Mismatches 7;	Indels 1;
				Gaps 1.

QY	1036	ttctatgaggaacacacccctgaggagatcttgaagaatttgatctcagcgcggagaagat	1095
Db	1	TTTCATATGGAGAACACCTGAGGAGATCTGAAAGATTGGATTCCACCGGGAAGAAAT	60
QY	1096	ttaacagcttaactcagatataaa tca ttgaaagttaa taagfcaaaagctagctctaact	1155
Db	61	TTATCACTTAACCTACAGATATAATTCATTGAAAGTAAATAGGTAAGCTAGCTCTTAAT	120
QY	1156	tccagagccacagcgtcagaatcttgaatctgcacattacagcttagagatcacataa	1215
Db	121	TTCCAGCGCCACGGCTCAAGTGAATTTGAATTACTGCATTTACAGTGTAAAGTAACACATAA	180
QY	1216	catgtatgcatgaaacatgagagacagattaacagtgctcctacacactcaatcaaga	1275
Db			

Db	181	CATGTATGCATGGAAACAGGAGGAAACAGTATTACAGTGTCTCACTCACTTAATCAAGA	240
Oy	1276	aaagaattaaagctcgcgatctcacggtgatattgaaattcctaaanaaacygtatcatcattg	1335
Db	241	AAAGAAATTACGACTCTGATTCTACAGTAGATGTAATTTAAATAAGTATATATTAG	300
Oy	1336	gaccttgattatctaaacaccttggactatatactaataatcagtagtattctgccttc	1395
Db	301	GGCTTTGATTATTAAACACTTGGTAGCTTAATCACTAAATTATGATGATTAATCTGCTTC	360
Oy	1396	cagtttccttgatatatttcttgatattbaagttcttgcctatatttggaaagtgctc	1455
Db	361	CAGTTTGCTGATATATTATTTTTATATTAGATTCTTGACTTATATTTTGAATGGGTTCT	420
Oy	1456	agtgaaaaaggaatgatatattcttgaagacatcgatatatactatttcaaccttctgat	1515
Db	421	ACTAAANAAGATGATATTCTTCTTAACACATCGATATACCTTTATTATTAACCTTGAT	480
Oy	1516	tctcaaatctagaanaatg-aggaatcgcacaacaattctgtatctgtatgaagtcacgt	1571
Db	481	TCTTCATATGTAGAAATGAAAGAAATGCCCCAAATTGTTGGTGATTAAGAATCCCGT	537

RESULT	5
ID	V58481/c
AC	V58481 standard; cDNA; 773 BP.
DT	08-DEC-1998 (first entry)
DW	5' fragment of prostate tumour specific gene Fl-12.
KV	Prostate tumour specific gene; human; prostate cancer; detection;
OS	therapy; ss.
PN	Homo sapiens.
PD	WO9837418-A2.
PF	27-AUG-1998.
PR	25-FEB-1998; UO3690.
PR	09-FEB-1998; US-904809.
PR	25-FEB-1997; US-806596.
PA	01-AUG-1997; US-904809.
PI	(CORI-) CORIXA CORP.
PI	Dillon DC, Xu J.
WPi:	98-480805/41.
PT	Novel human prostate specific tumour protein and fragments - useful
PS	for detecting and treating prostate cancers
CS	Claim 1; Page 35-36; 141pp; English.
CC	This sequence represents a human prostate tumour specific gene, and can
CC	be used in the method of the invention. The method is for detecting
CC	prostate cancer comprises contacting a biological sample with an agent
CC	able to bind an immunogenic portion of a prostate protein (such as
CC	encoded by this sequence). An antibody which binds to an immunogenic
CC	portion of the prostate protein, and the method can be used to detect,
CC	monitor progression of, or treat prostate cancers. The antibody may
CC	also be conjugated to a therapeutic agent for use in therapy of prostate
CC	cancers.
SD	Sequence 773 BP; 154 A; 242 C; 162 G; 197 T;

Query Match	25.1%	Score 406.6;	DB 1;	Length 773;
Best Local Similarity	98.6%;	Pred. No. 2e-75;		
Matches 409;	Conservative	0;	Mismatches 6;	Indels 0;
			Gaps	0

OY	615	gggaagaccccgagagacaaactcttgaatgcttgaagaccccttcataagacttaca	674
Db	415	ggggcccccttcgagacagAACATgTTGGATGGTGGAGCAcCTTTTATACAGCTTACA	356
OY	675	ggacagcagatctgggaaattcactgctctgagacaatagaaccacagttctacaagctgc	724
Db	355	GGACAGCGAGTGGGGATTCATGGCTGTTGGAGCAATAGAACCCCACTTTACAGCTGC	236
OY	735	tgatcaaaagaccttgaactaaagctctgtaaaccttcccaactcagaatgacatgtaatt	794
Db	295	TGATCAAAAGGANNITGGACTAAGCTGATGAACCTTCCCATCAGATGACATGATATTT	238
OY	795	ggccagaaattaaagaaagattctgcagatctatcttcaagaagaacgaaagcgaagtgc	854

Db 235 GGCAGAAATGAAGAGAGTTTGAGATGATTTGCAAAAGAGCAGAGAGTGT 176
QY 855 gtcaatctttgagcgagacatgcctgtgtactccggtctgacttttgaagagtg 914
Db 175 GTCAATCTTTGAGCGGACAGATGCTGTGACTCCGGTTCTGACTTTTGAGAGGTTG 116
QY 915 ttcatcatgatacaacaagaagcgaggtcgtttatcacagtgagagagagctga 974
Db 115 TTCAATCATGATCACAAGAGAGCGGGCTGTTTATCACCAGTAGAGAGAGAGCTGA 56
QY 975 gcccccgcctgcacactctgctgttaaacacccagccatcccttcttcaaaag 1029
Db 55 GCCCCCGCCCTGCACACTCTGCTGTTAAACACCAGCCATCCCTTCTTCAAAAG 1

RESULT 6

V61141/c

V61141 standard; cDNA; 773 BP.

DI 06-JAN-1999 (first entry)
DE 5' cDNA sequence of prostate tumour clone Fl-12.
KM Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN WO9837093-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; US-03492.
PR 09-FEB-1998; US-020956.
PR 25-FEB-1997; US-806099.
PR 01-AUG-1997; US-904804.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J.
DI WPI: 98-609886/51.
PT Polypeptides comprising immunogenic portions of prostate proteins -
used in a vaccine for the treatment of prostate cancer
PS Claim 3; Page 35; 130pp; English.
CC The present sequence is a new DNA which encodes an immunogenic portion
of a prostate tumour protein. The encoded immunogen, or the DNA itself,
can be used as a vaccine for the treatment of prostate cancer. The DNA
CC was identified by analysis of a subtracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
CC tissue cDNA library.
SQ Sequence 773 BP; 154 A; 242 C; 162 G; 197 T;

Query Match 25.1%; Score 406.6; DB 1; Length 773;

Local Similarity 98.6%; Pred. No. 2e-75; Mismatches 6; Indels 0; Gaps 0;

QY 615 ggaagacacccgcagagacagacatgttgatgtgtgagacaccccttcatacagattaca 674
Db 415 GGGCCCCCCTCGAGAGAGAGACATGTTGGATGTGTGAGACACCTTCTTACGATTTACA 356
QY 675 ggaacagatgaggggaattcatgctgtgttgagcaatagaaccagcttctcagagctgc 734
Db 355 GCAGACGAGATGGGGAATTGATGCTGTGGAGCAATAGAACCCAGTCTTCGAGCTGC 296
QY 735 tgatcaaaagagcttgatgaagctgtgatgaactcccaatcagatgagcatgattgatt 794
Db 295 TGATCAAAAGGANNMGATTAAGTGTGATGAATCTCCAAATCAGATGAGCATGAGATGATT 236
QY 795 ggcagaataaagaagaagatttgacagtatttgcaaaagaagaagcagaagtgatt 854
Db 235 GCCCAAGATGAAGAGAGAGTTTGCAGATGTTTTCAGAAAGAGCAGAGAGTGT 176
QY 855 gtcaaatctttgagcgagacatgcctgtgtactccggtctgacttttgaagagtg 914
Db 175 GTCAATCTTTGAGCGGACAGATGCTGTGACTCCGGTTCTGACTTTTGAGAGGTTG 116
QY 915 ttcatcatgatacaacaagaagcgaggtcgtttatcacagtgagagagagctga 974
Db 115 TTCAATCATGATCACAAGAGAGCGGGCTGTTTATCACCAGTAGAGAGAGAGCTGA 56

QY 975 gcccccgcctgcacactctgctgttaaacacccagccatcccttcttcaaaag 1029
Db 55 GCCCCCGCCCTGCACACTCTGCTGTTAAACACCAGCCATCCCTTCTTCAAAAG 1

RESULT 7

V58510

V58510 standard; cDNA; 793 BP.

AC V58510;
DI 08-DEC-1998 (first entry)
DE 3' fragment of prostate tumour specific gene K1-48.
KM Prostate tumour specific gene; human; prostate cancer; detection;
therapy; ss.
OS Homo sapiens.
PN WO9837418-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; US-03690.
PR 09-FEB-1998; US-904809.
PR 25-FEB-1997; US-806596.
PR 01-AUG-1997; US-904809.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J.
DI WPI: 98-480805/41.
PT Novel human prostate specific tumour protein and fragments - useful
for detecting and treating prostate cancers
PS Claim 1; Page 50; 141pp; English.
CC This sequence represents a human prostate tumour specific gene, and can
be used in the method of the invention. The method is for detecting
prostate cancer comprises contacting a biological sample with an agent
able to bind an immunogenic portion of a prostate protein (such as
CC encoded by this sequence). An antibody which binds to an immunogenic
CC portion of the prostate protein, and the method can be used to detect,
CC monitor progression of, or treat prostate cancers. The antibody may
CC also be conjugated to a therapeutic agent for use in therapy of prostate
CC cancers.
SQ Sequence 793 BP; 184 A; 200 C; 189 G; 200 T;

Query Match 24.9%; Score 403.2; DB 1; Length 793;

Best Local Similarity 97.1%; Pred. No. 1e-74; Mismatches 12; Indels 0; Gaps 0;

QY 630 gacagaacatgttgatgtgtgagacaccccttcatacagattacaagacagagatggg 689
Db 1 GACAGAAATGATGTGATGTGTGAGACACCTTCTTATACGACTTACAGAGACAGATGGG 60
QY 690 aattcagctgtgttgagacaaatagaaccagcttctacagagctgtgatacaagagcttg 749
Db 61 AATCATGCTGTGTGAGACCAATANAAACCCAGTCTTACGAGCTGCTGATCAAGACTTG 120
QY 750 gactaaagctgatagaattcccaatcagatgagcatgattgtggccaaatagaaga 809
Db 121 GACTTAAAGTCTGATGAATCTCCCAATCAGATGAGCATGATGATGGCCACAAATAGANA 180
QY 810 agaagcttgacagatgatttcgaagaagaagcagaagtgatgtgtcaaatcttgagc 869
Db 181 AGAAGTTTGCAGATGATTTTGCAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 240
QY 870 gacagatgctgtgtgacacccggtctgacttctgaagaggtgtgtcatcatgattaca 929
Db 241 GCACAGATGCTGTGTGACTCCGGTTCTGACTTTGAGAGAGTTGTTTCATCATGATCACA 300
QY 930 acaagaagcaggggtcgtttatcacacagtgagagcagaagtgagcccccgcctgtac 989
Db 301 ACAAGAAGCGGGGCTGTTTATCACCANTGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 360
QY 990 ctctgctgttaaacacccacacatcccttcttcaaaagagatcccttcataagagac 1049
Db 361 CTCTGCTTAAACAGCCCAACATCCCTTCTTCAAAAGGATCCACTACTTCTAGAGC 420

RESULT 8

V61276

AC V61276 standard; cDNA: 793 BP.
AC V61276:
DE 06-JAN-1999 (first entry)
DE 3' cDNA sequence of prostate tumour clone KI-48.
KW Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN WO9837093-A2.
PD 27-AUG-1998.
PF 25-FEB-1998: US-03492.
PR 09-FEB-1998: US-020956.
PR 25-FEB-1997: US-806099.
PR 01-AUG-1997: US-904804.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
PI WPI: 98-609886/51.
PT Polypeptides comprising immunogenic portions of prostate proteins -
PT used in a vaccine for the treatment of prostate cancer
PS Claim 12: Page 48-49; 130pp: English.
CC The present sequence is a DNA which encodes an immunogenic portion
CC of a prostate tumour protein. The encoded immunogen, or the DNA itself,
CC can be used as a vaccine for the treatment of prostate cancer. The DNA
CC was identified by analysis of a subtracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
CC tissue cDNA library.
SQ Sequence 793 BP: 184 A: 200 C: 189 G: 200 T:

Query Match 24.9%; Score 403.2; DB 1; Length 793;
Best Local Similarity 97.1%; Pred. No. 1e-74;
Matches 408; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 630 gacagacatgttgatgagtgagacaccccttcatacagacttaacagacagatgagg 689
DB 1 GACAGACATGTTGATGAGTGAGACACCTTCTATACGACTTACAGACAGCAGATGGG 60
QY 690 aattcagctctctgtgagagaatagaaaccccaatctcaagagctgcagatcaagagcttg 749
DB 61 AATTCTAGCTCTGTGAGAGCAATNAAACCCAGTTCTACAGCTGCTGATCAAAAGACTTG 120
QY 750 gactaaagctcagtgacttcccaatcagatgagacatgagatgagtgagcagaatgaaga 809
DB 121 GACTAAAGCTGATGAACTTCCCAATCAGATGAGATGATGATGGCCAGAAATGAANA 180
QY 810 aagaagcttcagatgatttttcaagaagaagcagagcagagtggttcaaatcttgaag 869
DB 181 AAGAAGTTTCAGATGATTTTGCAGAAAGAGCAGAGAGTGATGATCAATCTTGACG 240
QY 870 gacacagatcctgtgagactcggcttcgacttttgaagagtggttcatacagacaca 929
DB 241 GCACAGATCCCTGTGTGACTCCGCTTCTGACTTTGAGAGGTTGTCATCATGATCACA 300
QY 930 acaagaagaaggagctcgtttatcaccagtgagagcagagcgtgagcccgccctgcac 989
DB 301 ACAANAAGGGGCTGTTTATCACCANTGAGAGCAGACGAGACCCCGCCCTGCAC 360
QY 990 ctctcgtcttaaacacccacgacatccctcttcaaaaggagatccttcatacaggaac 1049
DB 361 CTCTGCTGTTAAACACCCAGCATCCCTCTTTCAAAAGGATCCACACTCTCTAGAG 420

RESULT 9
V58480
ID V58480 standard; cDNA: 816 BP.
AC V58480:
DE 08-DEC-1998 (first entry)
DE 3' fragment of prostate tumour specific gene Fl-12.
KW Prostate tumour specific gene; human; prostate cancer; detection;
OS Homo sapiens.
PN WO9837418-A2.
PD 27-AUG-1998.
PF 25-FEB-1998: US-03690.
PR 09-FEB-1998: US-904809.

PR 25-FEB-1997: US-806596.
PR 01-AUG-1997: US-904809.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
PI WPI: 98-480805/41.
PT Novel human prostate specific tumour protein and fragments - useful
PT for detecting and treating prostate cancers
PS Claim 1: Page 35; 14pp: English.
CC This sequence represents a human prostate tumour specific gene, and can
CC be used in the method of the invention. The method is for detecting
CC prostate cancer comprises contacting a biological sample with an agent
CC able to bind an immunogenic portion of a prostate protein (such as
CC encoded by this sequence). An antibody which binds to an immunogenic
CC portion of the prostate protein, and the method can be used to detect,
CC monitor progression of, or treat prostate cancers. The antibody may
CC also be conjugated to a therapeutic agent for use in therapy of prostate
CC cancers.
SQ Sequence 816 BP: 189 A: 205 C: 208 G: 201 T:

Query Match 24.7%; Score 400.2; DB 1; Length 816;
Best Local Similarity 98.1%; Pred. No. 4.3e-74;
Matches 405; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 636 acatgttgagtgagagacaccccttcatacagacttaacagacagatgaggatca 695
DB 5 AATGTTGATGATGAGAGACACCTTCTATACGACTTACAGACAGACAGATGGGAATTC 64
QY 696 tggcgttgagacatagaaacccagtggttcaagactcgtgtaaaaggacttgactaa 755
DB 65 TGGCTGTTGACCAATAGAACCCAGTTCTACGACTGCTGATCAAAAGACTTGGACTTA 124
QY 756 agctcagtaacttcccaatcagatgagatgagatgagtgagcagaagaatgaagaagt 815
DB 125 AGCTGATGAACTTCCCAATCAGATGAGATGATGATGGCCAAATGAAGAAAGAACT 184
QY 816 ttgcagatgatttttcaaaagaagcagaagtgagtgatcaaatcttgaagcagacag 875
DB 185 TTGCAGATGATTTTCAAAAGAGAGAGAGAGAGAGTGATGATCAATCTTGACGACAG 244
QY 876 atgcccgtgtgactcggcttcgacttttgaagagtggttcatacagacacaaga 935
DB 245 ATGCCGTGTGACTCCGCTTCTGACTTTTGAAGAGGTTGATCATGATCAACAAGG 304
QY 936 aacggagctcgtttatcaccagtgagagcagagcagagcagcccgccctgcacttgc 995
DB 305 AACGGGCTGCTTATCACCAGTGAAGACAGACAGAGCTGAGCCCGCCCTGCACCTTGC 364
QY 996 tgttaaacacccacgacatccctcttcaaaaggatccttcatacaggaaga 1048
DB 365 TGTAAACACCCAGCATCCCTCTTTCAAAAGGATCCACTAGTTCTAGAA 417

RESULT 10
V61140
ID V61140 standard; cDNA: 816 BP.
AC V61140:
DE 06-JAN-1999 (first entry)
DE 3' cDNA sequence of prostate tumour clone Fl-12.
KW Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN WO9837093-A2.
PD 27-AUG-1998.
PF 25-FEB-1998: US-03492.
PR 09-FEB-1998: US-020956.
PR 25-FEB-1997: US-806099.
PR 01-AUG-1997: US-904804.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
PI WPI: 98-609886/51.
PT Polypeptides comprising immunogenic portions of prostate proteins -
PT used in a vaccine for the treatment of prostate cancer
PS Claim 3: Page 35; 130pp: English.

EH	Key	Location/Qualifiers
FT	Intron	1613. .1520
FT	Intron	/*tag= a
FT	Intron	3860. .3911
FT	Intron	/*tag= b
FT	Intron	4178. .4240
FT	Intron	/*tag= c
FT	Intron	4357. .4423
FT	Intron	/*tag= d
FT	Intron	4839. .4891
FT	Intron	/*tag= e
PN		J06038763-A.
PD		15-FEB-1994.
PF		12-MAR-1993; 077367.
PR		13-MAR-1992; JP-088418.
PA	(ASAH) ASAH CHEM IND CO LTD.	
DR	WPI: 94-094831/12.	
PT	A DNA fragment contg. a gene used in the bio-synthesis of cephalosporin C - used to produce recombinants with improved biosynthesis of cephalosporin C	
PT	Claim 5; Page 14-15; 199P; Japanese.	
CC	This sequence represents the cephalosporin C gene and was isolated from A. cristogenum. This gene fragment may be used in the biosynthesis of cephalosporin C and in the production of A. cristogenum strains with improved cephalosporin C fermentation capabilities.	
CC	Sequence 5537 BP; 1204 A; 1673 C; 1516 G; 1144 T;	

Query Match	14.5%	Score 234.8	DB 1	Length 5537
Best Local Similarity	57.1%	Pred. No. 9.1e-40		
Matches 491	Conservative 0	Mismatches 357	Indels 12	Gaps 3
OY 48	ccccgggcccgtctgtgtctatgtgtccctggcctgacttctggggcgcggtgtgtgaacgcgtg	107		
Db 1555	CTCCAGGGCCCATCTGTGTGACGATGCTTTGGCGAGACTATAGGCCCTCACTATACCCCATCG	1466		
OY 108	accggccccgcgtcccgctacgaacgtgtgaacgcgcttggccgggcaacgcctcgtcagtgc	167		
Db 1465	ACGGACCCCGATCCCCCAAGGGGAGCTC---TGGCAGAGAACAAATGTCATCTGCA	1409		
OY 168	tggacctgaagcaagccgcggggagccgcgctgtcgtcgcgcgctctgtgtcaacgcgtctgaltg	227		
Db 1408	TGGAATTGAACATCTCCGCTTCACCAAGAGTGTCTCTTCATCTGTATCCCGCGGGAGC	1349		
OY 228	tgcctctggagccctctccgcgcggtgtcatgtagaagaactccagcttggcgcc---cagaaga	284		
Db 1348	TGCTCATGTGACCCGCTCCGGCCCGCGCTCTGTGACAGCTCTGGGGCTTCTCCCCACAGAGC	1289		
OY 285	tctctgcaagcggaataatcaagagcttatattatgcccagagctgtgaattgtgacgtacag	344		
Db 1288	TCTCTCTCAAGGCGAATCCCGCTGGTGTGTGTGCGCCGCTACCGGGCTTCCGCGAGATG	1229		
OY 345	gaagctctgcgcgtttagctgtgcccacgatatcaattattgtcttctgttcaggtgtctct	404		
Db 1228	GCAAGTACACAGACATGTGCAGGCACTGATATCACTATACCTGCCGTGTCTGGCGTCTGG	1169		
OY 405	caaaatctgcaagaagtgtgtagaatctcgatgcccgcgtgaatctctctgtgactgtg	464		
Db 1168	CTATGCTTGTGTATGAGCGACAGCGAGATCCCTTCCCGCCGCAACATCTCGGGCACTTGG	1109		
OY 465	ctgtgtgtgtgccttatgtgtgcactgtggcattaaatgagctcttltgtgacgcgacaagaa	524		
Db 1108	CCGGGGGGGGCCATGTGCGTCTGTGGGAATTTCTGTGGCGCTGTATACGCGCATGCGCA	1049		
OY 525	ctgaacaaggtgcaggtctatgtatgaataatgtgtgaaggaacacatatatgaattctt	584		
Db 1048	CGGGCTTGGCCAGGCTCTCGAGGCGCAACATGTGTGAGAGGGGTCTCGTATCTGGCCACGA	989		
OY 585	tctctgtgaaaaactagaagaatcgaagctctgtgtggaagcacctctgagaacagaacatgttg	644		
Db 988	TGCCCGGCTGGCGACCAAGAGCGCCCTTGTGGGGTTCGCCGGGGGCGAGATGTCTCTGG	929		

OY	645	atggtgagacaccttctatacgaattacaggaca-----gcagatggggaattcatg	638
Db	928	ACGGAGGGGTGCCCCCTGGATGCGACATACCGGAAGAAGACCCCGGGGGGAGTACATGG	859
OY	639	ctgttgaggagaaatagaaccccaagcttcagagctgcctgcatacaagaagcttgactaaagt	758
Db	868	CCGTGGAGGCCCTGGAGCCTTACTTTTACAGAGTGTGTGTCGAGTCTTGCCCTGGACA	809
OY	739	ctgatgaacttcccaatcagatgacatgacatgatatgtttgcccagaataatgaagaagt	818
Db	808	AGACGACCTCCCTCCGCCGAGGAGATAGGGCCAAATTGGCCGAGACTGAGGCCCTTATTC	749
OY	819	cagatgatactttgcaagaagacggaagcagatgctgttcaactctttgacgacacaagt	878
Db	748	AGGCAAATTTTGGGAGAGGAGCGCGCAGCGAGTGGCGCGAGTCTTTGACGGGACGGATG	669
OY	879	ccctgtgtgactccggtctctg	898
Db	688	CTGTGCTACCCCGGATCCTG	669

RESULT	13
ID	T59701
AC	T59701 standard; DNA; 2123 BP.
DT	07-JUL-1997 (first entry)
DE	PTH-like peptide DNA clone HHM-4.
KM	PTH-like peptide; parathyroid hormone; parathormone; agonist;
KM	adenylate cyclase; humoral hypercalcaemia of malignancy; HHM;
KM	tumour marker; cancer; diagnosis; ss.
OS	Homo sapiens.
PH	Key
FT	5'utr
FT	1..938
FT	/*tag- a
FT	939..1547
FT	/*tag- b
FT	939..1046
FT	signal.peptide
FT	939..1046
FT	/*tag- c
FT	mat.peptide
FT	1047..1544
FT	/*tag- d
FT	1545..2123
FT	/*tag- e
FT	2006..2011
FT	/*tag- f
FT	1062..1099
FT	/*tag- g
FT	/note= "nucleotide region corresponding to probe used to screen SKRC-1 cDNA library"
FT	
PI	US6603815-A.
PN	25-FEB-1997.
PD	25-FEB-1997.
PF	14-MAR-1988; 167593.
PR	14-MAR-1988; US-167593.
PR	18-FEB-1992; US-639722.
PR	21-JUN-1994; US-263242.
PA	(UYXA) UNIV YALE.
PI	Broadus AE, Mangin M, Stewart AF;
PI	WPI; 97-153577/14.
DR	P-PSDB: M12725.
PT	DNA encoding parathyroid hormone-like peptide - for prodn. of recombinant peptide; used to diagnose humoral hypercalcaemia of PTH malignancy
PS	Claim 2: Fig 1, Fig 8; 15PP: English.
CC	DNA clones HHM-8 (T59700) and HHM-4 (T59701) code for PTH-like peptides (M12724 and M12725, respectively), which are humoral mediators of humoral hypercalcaemia of malignancy (HHM). A cDNA library prepd. from SKRC-1 cells, which secrete HHM factor, was screened with a probe based on amino acids 6-18 of the N-terminal region of an isolated PTH-like peptide, to isolate the 2 strongly positive clones, lambda HHM-4 and HHM-8. These clones, or portions of them coding for the mature peptide or for the mature peptide plus leader, can be incorporated into vectors and used to produce recombinant PTH-like peptides in host cells for use in the diagnosis of HHM. The HHM sequences are derived from human chromosome 12.

35	59.2	3.7	1582	1	T28259	Survival motor neu
36	59.2	3.7	2001	1	T59700	PTH-like peptide D
37	59.2	3.7	2427	1	Q04107	Human pro-urokinas
38	58.6	3.6	2233	1	V10120	Human retinoid rec
39	58.6	3.6	2377	1	Q20360	Human pro-urokinas
40	58.6	3.6	6644	1	X33181	Base sequence of t
41	58.6	3.6	7372	1	X33182	Base sequence of t
42	58.6	3.6	7797	1	X33180	Cowpox virus bsr f
43	58.6	3.6	7996	1	X33184	Base sequence of t
44	58	3.6	1536	1	Q94111	mML genomic DNA. T
45	58	3.6	2271	1	V84632	Human secreted pro

ALIGNMENTS

RESULT 1
V58584
ID V58584 standard; cDNA; 1621 BP.
AC V58584;
DT 08-DEC-1998 (first entry)
DE Prostate tumour specific gene clone F1-12.
KW Prostate tumour specific gene; human; prostate cancer; detection;
KW therapy; ss.
OS Homo sapiens.
FH Key Location/Qualifiers
FT CDS 5..1153
FT /*tag= a
PN WO9837418-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; U03690.
PR 09-FEB-1998; US-904809.
PR 25-FEB-1997; US-806596.
PR 01-AUG-1997; US-904809.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI; 98-480805/41.
DR P-PSDB; W69383.
PT Novel human prostate specific tumour protein and fragments - useful
PT for detecting and treating prostate cancers
PS Claim 1; Page 81-82; 141pp; English.
CC This sequence represents a human prostate tumour specific gene, and can
CC be used in the method of the invention. The method is for detecting
CC prostate cancer comprises contacting a biological sample with an agent
CC able to bind an immunogenic portion of a prostate protein (such as
CC encoded by this sequence). An antibody which binds to an immunogenic
CC portion of the prostate protein, and the method can be used to detect,
CC monitor progression of, or treat prostate cancers. The antibody may
CC also be conjugated to a therapeutic agent for use in therapy of prostate
CC cancers.
SQ Sequence 1621 BP; 461 A; 330 C; 412 G; 418 T;

Query Match 100.0%; Score 1621; DB 1; Length 1621;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1621; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	cgccatggcactgcagggcatctcggtcatggagctgtccggcctggccccgggcccgtt	60
Db	1	CGCCATGGCACTGCAGGGCATCTCGGTATGGAGCTGTCCGGCCTGGCCCCGGGCCGTT	60
Qy	61	ctgtgctatggctcctggctgacttcggggcgcggtgtggtacgctggaccggccccggctc	120
Db	61	CTGTGCTATGGTCCTGGCTGACTTCGGGGCGCGTGTGGTACGCGTGGACGGCCCCGGCTC	120
Qy	121	ccgctacgacgtgagccgcttggggccggggcaagcgctcgtagtgctggacctgaagca	180
Db	121	CCGCTACGACGTGAGCCGCTTGGGCCGGGGCAAGCGCTCGCTAGTGTGGACCTGAAGCA	180
Qy	181	gcccgggggagccgctgctgctggcgctgtgtgcaagcggtcggtatgtgctgctggagcc	240
Db	181	GCCGCGGGGAGCCCGCTGCTGCGGCGTGTGTGCAAGCGGTGCGATGTGCTGCTGGAGCC	240

This Page Blank (uspto)

```

QY 241 ctccgcgcggggtcattgagaaacccagctggccagagattctgcagcgggaaaa 300
DB 241 ctccgcgcgcgggtctcatgagaaactccagctggccagagattctgcagcgggaaaa 300
QY 301 tccaaagctattatgacagagctgagtgattggccagtcagaaagctcttcgcttc 360
DB 301 tccaaagctattatgacagagctgagtgattggccagtcagaaagctcttcgcttc 360
QY 361 agctggccagagatacacaactatttgcttcagagtgctctcccaaaaattggcagaag 420
DB 361 agctggccagagatatacaactatttgcttcagagtgctctcccaaaaattggcagaag 420
QY 421 tggtagaagatccgtaagcccgctgaaatcccgctgagcttgctggctggctggct 480
DB 421 tggtagaagatccgtaagcccgctgaaatcccgctgagcttgctggctggctggct 480
QY 481 gttgacatgggcaataatgctctcttggccgacacgacatgacagagtgaggt 540
DB 481 gttgacatgggcaataatgctctcttggccgacacgacatgacagagtgaggt 540
QY 541 catgatgcaataatgctgagaaagacagacatacttaagctctcttcgtggaaactca 600
DB 541 catgatgcaataatgctgagaaagacagacatacttaagctctcttcgtggaaactca 600
QY 601 gaaatcgagctctgaggaaagacaccccgagagacagaaatgtagtggtgagacacttt 660
DB 601 gaaatcgagctctgaggaaagacaccccgagagacagaaatgtagtggtgagacacttt 660
QY 661 ctatgacacttacaagacagacagatggggaattcagctgctgaggcaatagaaaccca 720
DB 661 ctatgacacttacaagacagacagatggggaattcagctgctgaggcaatagaaaccca 720
QY 721 gttcagagctcgtcatcaaaagacttgacaaagtctgtagaacttcctccatcagat 780
DB 721 gttcagagctcgtcatcaaaagacttgacaaagtctgtagaacttcctccatcagat 780
QY 781 gagcatgagatgattgcccagaaatgaaagaagattgacagatgatttgcagaaagaagac 840
DB 781 gagcatgagatgattgcccagaaatgaaagaagattgacagatgatttgcagaaagaagac 840
QY 841 gaaagcagagtggtgctcaaatcttgaagcgacagatgctgtgtaacctggcttcagac 900
DB 841 gaaagcagagtggtgctcaaatcttgaagcgacagatgctgtgtaacctggcttcagac 900
QY 901 ttctggagagtggtgctcatcatgatacacaagaagagcggtgcttataccagatga 960
DB 901 ttctggagagtggtgctcatcatgatacacaagaagagcggtgcttataccagatga 960
QY 961 ggaagcagagctgagaccccgctgacactgctgtttaaaccaccccgacatcccttc 1020
DB 961 ggaagcagagctgagaccccgctgacactgctgtttaaaccaccccgacatcccttc 1020
QY 1021 ttcaaaaaggagctcttcatagagaaacacactgagagatacttgaattggatt 1080
DB 1021 ttcaaaaaggagctcttcatagagaaacacactgagagatacttgaattggatt 1080
QY 1081 cagcgccgagagagattatcagacttaactcagataaaatcatgaaagaaagaaagttaa 1140
DB 1081 cagcgccgagagagattatcagacttaactcagataaaatcatgaaagaaagaaagttaa 1140
QY 1141 agctagcttcaacttccagggcccaagcgctcaagtgaaattgaaatcattgacatgag 1200
DB 1141 agctagcttcaacttccagggcccaagcgctcaagtgaaattgaaatcattgacatgag 1200
QY 1201 tagagtaaacatacaatctgtatgcaatggaacatgagagaaacagatattacgtgtccta 1260
DB 1201 tagagtaaacatacaatctgtatgcaatggaacatgagagaaacagatattacgtgtccta 1260
QY 1261 caactcattcaaaaagaatatacagactgattctacagatgattgattgattgattgatt 1320
DB 1261 caactcattcaaaaagaatatacagactgattctacagatgattgattgattgattgatt 1320
QY 1321 aatggtatcatlaagagcttctgatttataaaacttgggtactataactaatatgatt 1380

```

```

DB 1321 aatggtatcatlaagagcttctgatttataaaacttgggtactataactaatatgatt 1380
QY 1381 agtattctgacctccagtttgcttataatttggattatgattgattgattgattgatt 1440
DB 1381 agtattctgacctccagtttgcttataatttggattatgattgattgattgattgatt 1440
QY 1441 ttctgaatgggtctcagtgagaaagaaatgatacttcttgaagacatgatactatcatt 1500
DB 1441 ttctgaatgggtctcagtgagaaagaaatgatacttcttgaagacatgatactatcatt 1500
QY 1501 attacactcttgattctcaatgtagaaatgagaaatgacacaaatgtagtgatt 1560
DB 1501 attacactcttgattctcaatgtagaaatgagaaatgacacaaatgtagtgatt 1560
QY 1561 aaaaagtcagtgagaaagaaagaaagaaagaaagaaagaaagaaagaaagaaagaa 1620
DB 1561 aaaaagtcagtgagaaagaaagaaagaaagaaagaaagaaagaaagaaagaaagaa 1620
QY 1621 a 1621
DB 1621 A 1621

RESULT 2
ID V61199 standard; cDNA; 1621 BP.
AC V61199:
DT 06-JAN-1999 (first entry)
DE Full length cDNA sequence of prostate tumour clone F1-12.
KW Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN M09837093-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; U03492.
PR 09-FEB-1998; U5-020956.
PR 25-FEB-1997; U5-806099.
PR 01-AUG-1997; U5-904804.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI: 96-609886/51.
DR P-PSDB: W71867.
PT Polypeptides comprising immunogenic portions of prostate proteins -
PS used in a vaccine for the treatment of prostate cancer
PS Claim 3, Page 76-77, 130pp. English.
CC The present sequence is a new DNA which encodes an immunogenic portion
CC of a prostate tumour protein. The encoded immunogen, or the DNA itself,
CC can be used as a vaccine for the treatment of prostate cancer. The DNA
CC was identified by analysis of a subtracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
CC tissue cDNA library.
SQ Sequence 1621 BP; 461 A; 330 C; 412 G; 418 T;

Query Match 100.0%; Score 1621; DB 1; Length 1621;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1621; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 cgcattggcactgagggcgcattcgtcatgagctgctcggcctggccggccgctt 60
DB 1 cgcattggcactgagggcgcattcgtcatgagctgctcggcctggccggccgctt 60
QY 61 ctgtgcatggtctcgtgctgacttcggggcggtgtgtacagcgctgagccggcctc 120
DB 61 ctgtgcatggtctcgtgctgacttcggggcggtgtgtacagcgctgagccggcctc 120
QY 121 ccgttacagctgagcgcttggggcggggcaagcgctgctgattgtgtaacctggaagca 180
DB 121 ccgttacagctgagcgcttggggcggggcaagcgctgctgattgtgtaacctggaagca 180
QY 181 gcccggggagccgcgctgctgagcgctgctgtgcaagcgctgagtgctgctgagcc 240
DB 181 gcccggggagccgcgctgctgagcgctgctgtgcaagcgctgagtgctgctgagcc 240

```

This Page Blank (uspto)

QY 241 ctccgcgcgcgtgcatgagaaactccagctcggcccaagaaattctcagcgggaaaa 300
DB 241 CTCGCCCGGGGTGATGAGAACTCCAGCTGGGCCCGAGAGATCTGACGGGAAAA 300
QY 301 tccaaagctatttaagcagcgtcagtgatctggccagtcaggaagcttcggccggtt 360
DB 301 TCCAAAGCTTATTATGCCAGGCTGAGTGATTTGGCCACTCGAAGACTTCTGCCGTT 360
QY 361 agctggcacaagatatacaactattggcttgatcagtggtctctcaaaaaattggcagaag 420
DB 361 AGCTGGCCAGATATCAACTATTGGCTTGCTCAGGTCTCTCCAAAAATTGGCAGAAG 420
QY 421 tggtagaactccgaatgccccgcgtgaactctccgctgacttgctgctgctgcttat 480
DB 421 TGGTAGAATTCCTGATCCCGCGGTGAATCTCTGGCTGACTTTCGTGTGTGCTTAT 480
QY 481 gctgcacctgggcaataatgctcttttgaccgcacacgcctgacaaaggctcaggt 540
DB 481 GTGTCACCTGGGCAATTAATGGCTCTTTTGACCGCACGCACTGACAAAGGCTCAGGT 540
QY 541 cattgatgcaaatatggtggaaggaacagcaatattgaattcttctgtagaaactca 600
DB 541 CATTGATGCAAAATATGGTGAAGGACAGCATATTAACTTCTTCTGTGGAATACTCA 600
QY 601 gaaatcgagctctggaagcagcctcgagacagaaacatgttgatggtggaagcacttc 660
DB 601 GAAATCGAGCTCTGGGAGAGCACTCGAGACAGACATGTGATGGTGGAGCACCTTT 660
QY 661 ctatacgactacaggaagcagatgaggaaatcagtgctgtggaagaataagaaaccca 720
DB 661 CTATCGACTTACAGGACAGAGATGGGGAATTCATGGCTGTGGAGCAATGAAACCCA 720
QY 721 gttctcagagctcgtatcaaaagagcttgagctaaagctgatatgaactcccaatcagat 780
DB 721 GTTCTACGAGCTGCTGATCAAAAGGACTTGAGTAAAGTCTGHTGAACCTTCCCAATCAGAT 780
QY 781 gaggatgagatgattggcagaaatgaagaagaatttcagatgatttgcagaaagaagac 840
DB 781 GAGCATGAGTGTGGCCGGAATTAAGAGAGAGTTTGCAGATGATTTGCCAAAGAGAC 840
QY 841 gaaagcagagtggtgtcaaatctttgacggcagacagatgctgtgactccggtctgac 900
DB 841 GAAAGCAGAGTGTGTCAAACTTTGACGGCACAGATGCTGTGACTCCGGTCTGTGAC 900
QY 901 ttctgagaggttggttcatcatgatacaaaagaagaagggctcgtttatcaccaagtga 960
DB 901 TTTTGAGAGGTTGTTCAATCATGATCACAACAAAGGAGCGGCTGTTATCACCAAGTGA 960
QY 961 ggaagcagagacgtgagcccccccgccctgacactctgctgttaaacaccccgccatcccttc 1020
DB 961 GGAGCAGAGACGTGAGCCCCCGCCCTGACCTCTGCTGTTAAACACCCGACCATCCCTTC 1020
QY 1021 ttcaaaaaggatccttcataggaagacacactgagagatacttgaagaatttggatt 1080
DB 1021 TTTCAAAAGGATCTTTTATAGAGAAACACACTGAGAGATCTTGAAGAAATTGGATT 1080
QY 1081 caagccggaagattatcatcagcttaactcagaataaataatcgaagtaagtaagtaaa 1140
DB 1081 CAGCCGGAAGATTTATCAGCTTAATCAGATAAAATCATGAAAGTAATAGGTAA 1140
QY 1141 agctagctcctaacctccagggcccaagcgtcgaagtgaatttgaattactgattcagtg 1200
DB 1141 AGCTAGCTCTTAATCTCAAGCCCAAGGCTCAAGTGAATTTGAATCTGATTTACAGTC 1200
QY 1201 taagagtaaccataaacttcatgaggaagacatgaggaacagtaattacagtgctccta 1260
DB 1201 TAGAGTAACACATTAATTTATGATGGAATAACATGAGAGACAGTATTACAGTCTTA 1260
QY 1261 ccaacttaacaaagaagaattacagactgattctacagtgatgattgaattcctaaa 1320
DB 1261 CCACTTAATCAAGAAAGAAATTACAGACTGTGATTTACAGTGTGATTTGAATTTCTMA 1320

QY 1321 aatggtatcatlaaggcttttgattataaacttgggaacttactactaattatgt 1380
DB 1321 AATGGTATCATTAAGGCTTTTGATTATTAACCTTGGGTACTTATTAATTAATGT 1380
QY 1381 agttatctgccttcaggttgcctgatatatttctgatatlaagatcttgaactata 1440
DB 1381 AGTTATCTGCCTTCAGGTTTGCCTGATATATTGTGATATTAAAGATCTTGACTATA 1440
QY 1441 tttagatggttctagtgaaaaaggaatgatalatcttgaagacatgatatatactt 1500
DB 1441 TTTGAATGGCTCTGATGAATAAGGATGATATATTCTGAAGACATCATATACATTT 1500
QY 1501 atttaactcttgatctcacaatgtagaaatgaggaatgccaacaattgtagtgat 1560
DB 1501 ATTTAACCTCTGATCTCAATGTGAAAAATGAGAAAAATGCCCAATTTGATGTGAT 1560
QY 1561 aaaaagcagtgtagaaaaaagaaaaaagaaaaaagaaaaaagaaaaaagaaaaa 1620
DB 1561 AAAAGTCAGCTGAACAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAA 1620
QY 1621 a 1621
DB 1621 A 1621

RESULT 3
V58551
IN ***-***

This Page Blank (uspto)

Interferon-pseudo
insulin receptor s
chimeric G-CSF-Flt3
LRP5 isoform 4 CD
POU domain transcr
Dog 32 kd alveolar
Canine 32k alveolar
Flt-3 and IL-3 ch
Flt3L/IG2b/G-CSF
Flt3L/IG2b/G-CSF

RESULT 2

ID	standard;	CDNA;	385 BP
V61287			

ID	standard;	CDNA;	385 BP
V61287			

Db	61	GGTCGGACCCAGCCACATCTATGCGAAGATTGCCCGAGACATCGATGCTAGAGATTTC	120
Qy	121	ccctctcaaaaaaggggagctctgtcttaaaaaagaagctcagcccgatctgtgtagagcagc	180
Db	121	CCCTTTAAAAAAGGGGACTTGCCTTAAAAAAGAGCTTACCCAGATTGTGTAGAGCAGC	180
Qy	181	tgtgtctgtctgtagatcacctttgagagagttccctcttgagaccgtactttagag	240
Db	181	TGTGCTGTGCTGGAGATTCACTTTTGAGAGAGTCTCTGTGAGACCTGATCTTTAGAGC	240
Qy	241	ctgggagagctcttgacacttgagatggaggtctgtctcgaactcaagcactcttaagctgttg	300
Db	241	CTGGGCGAGTCTTGACACATGAGATGGGGCTGTGTGATCTAGGACCTCTTAGCTGGTTG	300
Qy	301	ccctctccagggcccacagccctgtgagcaacctgtcttaccaggagactccagatgccatc	360
Db	301	CCCTCTCCCAAGGCCCCAGCCTGGCGACACCTGCTTACAGGGCACCTCTCAGATGCCCAATAC	360
Qy	361	catagttctctgtctagttagagcgt	385
Db	361	CATAGTTCTCTGTGCTAGTAGCGCT	385

This Page Blank (uspto)

34	28.2	1.3	6139	1	V/0354	Coding strand of
----	------	-----	------	---	--------	------------------

241 ctgggca
QY

Db 241 CTGGGCAGTCTTGCACATGAGATGGGGCTGGTCTGATCTCAGCACTCCTTAGTCTGCTTG 300

QY 301 cctctccagggcccgagctggccacacactgtctacagggcactctcagatggccatc 360
DB 301 CCTGTCGCCAGGGCCCGAGCCTGGCCACACTGCTTACAGGGCAGCTCAGATGCCCATAC 360
QY 361 catagttctgtgtcagtagtgacct 385
DB 361 CATAGTTCTGTGTAGTAGGACCGT 385

RESULT 2

V61287
ID V61287 standard; cDNA; 385 BP.
AC V61287;
DE 06-JAN-1999 (first entry)
DR CDNA sequence of prostate tumour clone P80.
KM Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN MO9837093-A2.
PD 27-AUG-1998.
PR 25-FEB-1998; U03492.
PR 09-FEB-1998; US-020956.
PR 25-FEB-1997; US-806099.
PR 01-AUG-1997; US-904804.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI; 98-609886/51.
PT Polypeptides comprising immunogenic portions of prostate proteins -
PI used in a vaccine for the treatment of prostate cancer
PS Claim 12; Page 61; 130pp; English.
CC The present sequence is a DNA which encodes an immunogenic portion
CC of a prostate tumour protein. The encoded immunogen, or the DNA itself,
CC can be used as a vaccine for the treatment of prostate cancer. The DNA
CC was identified by analysis of a subtracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
CC tissue cDNA library.
SQ Sequence 385 BP; 86 A; 105 C; 94 G; 100 T;

Query Match 100.0%; Score 385; DB 1; Length 385;

Best Local Similarity 100.0%; Pred. No. 3.5e-119; Mismatches 0; Indels 0; Gaps 0;
Matches 385; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 actaacacactccactgacctgtgtgagacactgtgtccagacatttagaagtctga 60
DB 1 ACTACACACACTCCACTTGCCTTGAGAGACACTTGTCCAGCACTTAGGAATGCTGA 60
QY 61 ggtggaccagcagcatctcattgtgcaaatgtgcccagacagatcaggtctcgaggttc 120
DB 61 GGTGGACCGACACATCTCATGTGCAAGATTGCCAGCAGACATCAGGTGTGAGAGTTTC 120
QY 121 ccccttaaaaaaggagacttgcttaaaaaaggagctcagccagactgtgtgagagcagc 180
DB 121 CCTTTAAAAAAGGGGACTTGTCTTAAAAAAGAGCTAGCCAGCATCTGTAGACACAC 180
QY 181 tgtgtgtgtgtgtgagatctcactttgagagagttctcctctgagacctgaccttagagg 240
DB 181 TGTGTGTGTGTGTGAGATCTTCTTGTAGAGAGTTCTCTGTAGAGACTGATCTTAGAGG 240
QY 241 ctgggagagcttgacatagatagggctgtgtgtcttcacagacctctagtctcttg 300
DB 241 CTGGGAGAGCTTGTGACATAGATAGAGGGGCTGTGTGATCTCAGACATCTTAGTCTCTTG 300
QY 301 cctctccagggcccgagctggccacacactgtctacagggcactctcagatggccatc 360
DB 301 CCTGTCGCCAGGGCCCGAGCCTGGCCACACTGCTTACAGGGCAGCTCAGATGCCCATAC 360
QY 361 catagttctgtgtcagtagtgacct 385
DB 361 CATAGTTCTGTGTAGTAGGACCGT 385

RESULT 3

V58544/c

ID V58544 standard; cDNA; 385 BP.

AC V58544;
DE 08-DEC-1998 (first entry)
DR Prostate tumour specific gene clone P80.
KM Prostate tumour specific gene; human; prostate cancer; detection;
KM therapy; ss.
OS Homo sapiens.
PN MO9837418-A2.
PD 27-AUG-1998.
PR 25-FEB-1998; U03690.
PR 09-FEB-1998; US-904809.
PR 25-FEB-1997; US-806596.
PR 01-AUG-1997; US-904809.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI; 98-480805/41.
PT Novel human prostate specific tumour protein and fragments - useful
PT for detecting and treating prostate cancers
PS Claim 1; Page 64; 141pp; English.
CC This sequence represents a human prostate tumour specific gene, and can
CC be used in the method of the invention. The method is for detecting
CC prostate cancer comprises contacting a biological sample with an agent
CC able to bind an immunogenic portion of a prostate protein (such as
CC encoded by this sequence). An antibody which binds to an immunogenic
CC portion of the prostate protein, and the method can be used to detect,
CC monitor progression of, or treat prostate cancers. The antibody may
CC also be conjugated to a therapeutic agent for use in therapy of prostate
CC cancers.
SQ Sequence 385 BP; 86 A; 105 C; 94 G; 100 T;

Query Match 21.8%; Score 84; DB 1; Length 385;

Best Local Similarity 64.5%; Pred. No. 1e-18; Mismatches 80; Indels 2;
Matches 160; Conservative 0; Mismatches 80; Indels 2;

QY 48 ttagaatgtcaggtcggaccagccacatctcatgtgcaagatgcccagc---agac 103
DB 48 TTAGAGAGTCTGATGATCAGACAGCCCATCTCATGTGCAAGACTGCGACCTCTAAAG 232
QY 104 atcagagctcagagagctccctcttaaaaaaggagagctgtcttaaaaaaggagctcagca 163
DB 104 ATCAGAGCTCAGAGAGAACTCTCTCAAAAAGGAATCTCCAGACAGCAGCTGCTCTTA 172
QY 164 cgaatgtctagagcagctgtgtgtgtgtgagatcactttgagagagttctcctctga 223
DB 164 CAGATCGTGCCTAGACTCTTCTTTTAAAGCAAGTCCCTTTTAAAAAGGGAATCTCA 112
QY 224 gacctgacctttagagagctggcagctctgtcacatgagatgggagctgtgtatctcagc 283
DB 224 GACCTGATGTCF---GCTGGCAGATCTTGACATGAGATGTGCTGCGACCTCAGC 56
QY 284 actcctta 291
DB 284 ATTCCTAA 48

RESULT 4

V61287/c
ID V61287 standard; cDNA; 385 BP.
AC V61287;
DE 06-JAN-1999 (first entry)
DR CDNA sequence of prostate tumour clone P80.
KM Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN MO9837093-A2.
PD 27-AUG-1998.
PR 25-FEB-1998; U03492.
PR 09-FEB-1998; US-020956.
PR 25-FEB-1997; US-806099.
PR 01-AUG-1997; US-904804.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI; 98-609886/51.

CC Chemokine activity, haemostatic and thrombolytic activity, receptor
CC Ligand activity, anti-inflammatory activity, tumour inhibition activity

Qy	50	aggaatgctgaagtcgacacagccatctcatgtgcaagatgcccacagacacagc	109
Best local similarity	72.5%	Prev. NO. 0.0059	
Matches	47	Conservative	0; Mismatches 18; Indels 0; Gaps 0

```
DB 100 AGAGTGCTCAGGTCACACCATCCCACTTATCGCAAGAACGCCCTGACTGATCAGG 41
QY 110 tctga 114
    |||||
DB 40 TCTGA 36

RESULT 7
ID 078233/c
ID 078233 standard; DNA: 1336 BP.
AC 078233:
DT 10-UTL-1995 (first entry)
DE Alkaline serine protease gene from Paecilomyces lilacinus.
KW Serine protease; nematode; egg; parasite; fungus; wheat; cabbage;
KW protease; primer; amplify; PCR; alkaline protease; parasitic nematode;
KW subtilisin-like protease; plant; plant cell; cyst; root-knot; lesion;
KW Heterodermidae; potato; sugar beet; cyst nematode; ds.
OS Paecilomyces lilacinus.
PN EP-623672-A.
09-NOV-1994.
04-MAY-1993: 107233.
04-MAY-1993: EP-107233.
PA (REPL.) RES INST PLANT PROTECTION.
PI Bonants PM, Den Bellder E, Filters PFL, Waalwijk C:
PI WPI: 94-343307/43.
PT Use of protease from Paecilomyces lilacinus - to control plant
PT parasitic nematodes esp. root-knot nematodes of potato plants
PS Claim 7: Page 15-16; 35pp; English.
CC The nucleotide sequence of the novel alkaline serine protease isolated
CC from the nematode egg parasitic fungus Paecilomyces lilacinus. The gene
CC encodes a protease of 33.5 kD which has an isoelectric point of pH10.
CC The protease has optimal activity at pH10.3 and 60 deg. C. The gene was
CC amplified from P. lilacinus genomic DNA using the primers (078234-5) based
CC on homologous amino acid sequence between the novel protease and a.a.
CC sequences which are conserved among subtilisin-like proteases. The
CC sequences include regions at the N-terminus of the protein (R65936) and
CC around the active site histidine residue (R65937). The resulting 240 bp
CC fragment was used to screen a P. lilacinus cDNA library in lambda ZAP to
CC obtain the full length gene encoding the protease. The protease is used
CC to control plant parasitic nematodes by controlling the action of the
CC nematodes on plants and plant cells. The gene encoding the protease can
CC be used to control plant parasitic cyst, root-knot or lesion nematodes
CC especially root-knot nematodes e.g. those in the Heterodermidae family
CC which include the potato and sugar beet cyst nematodes.
SQ Sequence 1336 BP; 307 A; 446 C; 318 G; 265 T;

Query Match 9.4%; Score 36.2; DB 1: Length 1336;
Best Local Similarity 49.7%; Pred. No. 0.016;
Matches 92; Conservative 0; Mismatches 93; Indels 0; Gaps 0;

QY 134 ggggacttcttaaaagaagctagccagattgtgtgagacagctgtgtctgtg 193
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 1047 GAGGACGTTCTTAGTAAGAAAGGCTGTGATGGCTTGACAGAGCGCTGGGCCCGGGA 988
QY 194 agattacattttagagagcttcctcctctgagacatgattcttagagagctgtgagctctg 253
    | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 987 AACCCGCCAGACCGCGAGTAGCGCCCGAGACCAACAATGTGGAGAGTGGCCATGGAAG 928
QY 254 cacatgagatgggctgtctgtatctcagcaactcctagtctgtctgtctctccagggc 313
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 927 TACCAAGAGATGTTGTGTAGTCCACCGAACGAGTGTGACAGAAATGTTGCTACCGGGG 868
QY 314 cccag 318
    |||||
DB 867 CGAAG 863

RESULT 8
ID V52306 standard; DNA: 4185 BP.
AC V52306:
DT 23-OCT-1998 (first entry)
```

```
DE Streptococcus pneumoniae genome fragment SEQ ID NO:173.
KW Streptococcus pneumoniae; S. pneumoniae; genome; diagnosis; assay;
KW computer readable medium; vaccine; pharmaceutical composition; ds.
OS Streptococcus pneumoniae.
PN M09818931-A2.
07-MAR-1998.
PD 30-OCT-1997: 019588.
PR 31-OCT-1996: US-029960.
PA (HUMA-) HUMAN GENOME SCI INC.
PI Barash SC, Choi GH, Dillon PJ, Dougherty BA, Fannon M,
PI Kunsch CA, Rosen CA:
PI WPI: 96-27225/24.
DR Computer-readable medium with recorded Streptococcus pneumoniae
PT polynucleotide sequences - useful in diagnostic kits and assays, and
PT pharmaceutical compositions and vaccines for Streptococcus
PT pneumoniae.
PS Claim 1: Page 1101-1103; 1409pp; English.
CC The present invention describes a computer readable medium which has
CC the nucleotide sequences SEQ ID NO:1 to 391 (V52134 to V52524) recorded
CC on it, or a representative fragment or a sequence at least 95% identical
CC to SEQ ID NO:1 to 391. The nucleotide sequences depicted in SEQ ID NO:1
CC to 391 (V52134 to V52524) are genomic fragments from Streptococcus
CC pneumoniae. The present invention also describes an isolated nucleic acid
CC molecule encoding a homologue of any of the fragments of the S. pneumoniae
CC genome (SEQ ID NO:1 to 391) where the nucleic acid molecule is produced
CC by a process comprising: (a) screening a genomic DNA library using as a
CC probe a target sequence defined by any of the sequences in SEQ ID NO:1
CC to 391, identifying members of the library which contain sequences
CC that hybridise to the target sequence and isolating the nucleic acid
CC molecules from the members; or (b) isolating mRNA, DNA or cDNA produced
CC from an organism, amplifying nucleic acid molecules whose nucleotide
CC sequence is homologous to amplification primers derived from the
CC fragment of the S. pneumoniae genome to prime the amplification and
CC isolating the amplified sequences. The computer readable medium can be
CC used in a computer-based system for identifying fragments of the
CC S. pneumoniae genome of commercial importance, or expression modulating
CC fragments of the S. pneumoniae genome. Products from the present
CC invention can be used in diagnosis kits and assays, and pharmaceutical
CC compositions and vaccines for S. pneumoniae.
SQ Sequence 4185 BP; 1257 A; 992 C; 749 G; 1187 T;

Query Match 8.7%; Score 33.4; DB 1: Length 4185;
Best Local Similarity 52.5%; Pred. No. 0.23;
Matches 73; Conservative 0; Mismatches 66; Indels 0; Gaps 0;

QY 125 cttaaaaaaggagacttcttaaaagaagctagccagattgtgtgagacagctgtg 184
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 1637 TTTTAAATCGGCTATCATATAGAAAAGATCTTCTTACTGCTAAAGATGACTG 1696
QY 185 cgtgtgtagagattcaacttttagagagagcttcctcctgagacattcttagagagctgg 244
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 1697 CAATGCTGGGGTCTTTTGGCCAGTTTCATTCGCAACTGAACTGACCTTTTGAGATAGA 1756
QY 245 gcagcttcgacatgagat 263
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 1757 CAAGTTATCCAGATTGCT 1775

RESULT 9
ID V23127/c
ID V23127 standard; cDNA: 5053 BP.
AC V23127:
DT 14-AUG-1998 (first entry)
DE cDNA of protein with Rho protein-combining and kinase activity.
KW Rho protein-binding activity; protein kinase activity; inhibitor;
KW smooth muscle fibre formation; smooth muscle contraction;
KW circulatory disease; treatment; tumour formation; metastasis inhibitor;
KW autoimmune disease; platelet aggregation inhibitor; ss.
OS Bos sp.
FS key Location/Qualifiers
FH 1. 4167
FT CDS
FT /tag= a
```

CC Cytoplasmic RNA was prepd. by using normal adult human skin

[illegible]

